1
|
Rosales-Castillo A, Bustos-Merlo A, Escobar Sevilla J. [The importance of genetics in the study of hypertriglyceridemia]. Hipertens Riesgo Vasc 2024; 41:132-134. [PMID: 38472008 DOI: 10.1016/j.hipert.2023.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 12/06/2023] [Accepted: 12/07/2023] [Indexed: 03/14/2024]
Abstract
Hypertriglyceridemia encompasses a set of lipid disorders common in clinical practice, generally defined as a fasting concentration above 150mg/dL. There are various classifications of the severity of hypertriglyceridaemia based on serum values, with levels generally considered moderate when below 500mg/dL and severe when above 1000mg/dL. Its importance lies in its association with other alterations in the lipid profile, contributing to increased cardiovascular risk and increased risk of acute pancreatitis, mainly with concentrations above 500mg/dL.
Collapse
Affiliation(s)
| | - A Bustos-Merlo
- Hospital Universitario Virgen de las Nieves, Granada, España
| | | |
Collapse
|
2
|
Amaro-Álvarez L, Cordero-Ramos J, Calleja-Hernández MÁ. Exploring the impact of pharmacogenetics on personalized medicine: A systematic review. Farm Hosp 2024:S1130-6343(24)00003-5. [PMID: 38341366 DOI: 10.1016/j.farma.2023.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 12/04/2023] [Accepted: 12/15/2023] [Indexed: 02/12/2024] Open
Abstract
INTRODUCTION Pharmacogenetics evaluates how genetic variations influence drug responses. Nowadays, genetic tests have advanced, becoming more affordable, and its integration is supported by stronger clinical evidence. Guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) and resources like PharmGKB facilitate genotype-based prescribing; and organizations like the FDA promote genetic testing before initiating certain medications. Preventive pharmacogenetic panels seem promising, but further research on biomarkers and diverse populations is needed. The aim of this review is to analyze recent evidence on the genotype-drug response relationship to examine how the genetic profile of patients influences the clinical response to treatments, and analyze the areas of research that need further study to advance towards a genetic-based precision medicine. MATERIALS AND METHODS A systematic search was conducted on PubMed to identify articles investigating the genotype-drug response relationship. The search strategy included terms such as "pharmacogenetics", "personalized treatment", "precision medicine", "dose adjustment", "individualizing dosing", "clinical routine", and "clinical practice." Clinical trials, observational studies, and meta-analyses published in English or Spanish between 2013 and 2023 were included. The initial search resulted in a total of 136 articles for analysis. RESULTS 49 articles were included for the final analysis following review by 2 investigators. A relationship between genetic polymorphisms and drug response or toxicity was found for drugs such as opioids, GLP-1 agonists, tacrolimus, oral anticoagulants, antineoplastics, atypical antipsychotics, efavirenz, clopidogrel, lamotrigine, anti-TNFα agents, voriconazole, antidepressants, or statins. However, for drugs like metformin, quetiapine, irinotecan, bisoprolol, and anti-VEGF agents, no statistically significant association between genotype and response was found. CONCLUSION The studies analyzed in this review suggest a strong correlation between genetic variability and individual drug responses, supporting the use of pharmacogenetics for treatment optimization. However, for certain drugs like metformin or quetiapine, the influence of genotype on their response remains unclear. More studies with larger sample sizes, greater ethnic diversity, and consideration of non-genetic factors are needed. The lack of standardization in analysis methods and accessibility to genetic testing are significant challenges in this field. As a conclusion, pharmacogenetics shows immense potential in personalized medicine, but further research is required.
Collapse
|
3
|
Ramírez Aranda JM, Martínez Gutiérrez CM, Fuentes Ramírez MM, Escobedo Ríos MR, Delgado Cuevas FDR. [Familial aggregation in Irritable Colon Syndrome in Mexican patients. A case-control study]. Aten Primaria 2024; 56:102794. [PMID: 37950999 PMCID: PMC10682529 DOI: 10.1016/j.aprim.2023.102794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 08/31/2023] [Accepted: 09/12/2023] [Indexed: 11/13/2023] Open
Abstract
OBJECTIVE To determine a family aggregation pattern of Irritable Bowel Syndrome (IBS). DESIGN it is a case-control study with a 1.2 ratio. SETTING External consultation of a general family medicine practice. PARTICIPANTS men and women from 18 to 60 years old. Cases (40): people with IBS according to the Rome IV criteria, and Controls (80): relatives without gastrointestinal disease. MAIN MEASUREMENTS Sociodemographic variables, related stressful events, predominant evacuation patterns, and family repetition patterns for IBS. Data were analyzed with descriptive and inferential statistics. Chi-square for categorical data (< p.05 as significant) estimate of ORs with 95% confidence interval. The institutional ethics committee approved it. RESULTS The IBS presentation pattern was repeated in relatives, mainly first-degree. The risk of suffering from IBS was higher when the father reported it (OR 11.2 (95% CI; 1.2 -100.1), than the mother OR 3,7 (95% CI; 1.4 - 9.9), sibling OR 2.8 (95% CI; 1.1 - 6.6. In both groups, the relative who most frequently presented IBS was in the collateral line (sibling) (37.5% in cases vs. 17.5% in controls (p=0.023). In both groups, the predominant gender was female, with 80. 0% in cases and 57.5% in controls. CONCLUSION SII has a familial recurrence pattern in the Mexican population. The disease is more frequent in first-degree relatives. It is important to elucidate the importance of the role that plays genetic background vs. the influence of the family environment in SII.
Collapse
|
4
|
García-Camarero T, Remuzgo-Martínez S, Genre F, López-Mejías R, Pulito-Cueto V, Veiga G, Lee Hwang DH, Sáinz Laso F, Gil Ongay A, González-Gay MÁ, de la Torre Hernández JM. Serum and genetic markers related to rapid clinical progression of coronary artery disease. Rev Esp Cardiol (Engl Ed) 2023; 76:1013-1020. [PMID: 37201714 DOI: 10.1016/j.rec.2023.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 04/24/2023] [Indexed: 05/20/2023]
Abstract
INTRODUCTION AND OBJECTIVES Patients with clinically evident coronary artery disease differ in their rate of progression, which impacts prognosis. We aimed to characterize serum and genetic markers in patients with rapid clinical progression (RCP) of coronary artery disease vs those with long standing stable (LSS) disease. METHODS Retrospective study of cases (RCP) and controls (LSS) (1:2). Patients requiring ≥ 2 revascularizations due to atherosclerotic progression in the 10 years after a first angioplasty were considered to be RCP and those without events during the same period after the first angioplasty were considered to have LSS disease. After patient selection, we analyzed serum values, mRNA expression and genetic polymorphisms of inflammatory markers, including interleukin-6, C-reactive protein, and tumor necrosis factor (TNF)-a, and atherogenic markers consisted of proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density lipoprotein receptor, sterol regulatory element binding transcription factor 2, and apolipoprotein-B. RESULTS The study included 180 patients (58 RCP and 122 LSS). Demographic characteristics, classic risk factors and the extent of coronary disease were similar in the 2 groups. Patients with RCP showed higher serum levels of interleukin-6 and PCSK9 and higher TNF mRNA expression. Interleukin-6 rs180075C, TNF rs3093664 non-G and PCSK9 rs2483205 T alleles conferred a risk of RCP (P<.05 in all cases). Among patients with RCP, 51.7% had all 3 risk alleles vs 18% of those with LSS (P<.001). CONCLUSIONS We suggest the existence of specific phenotypic and genotypic markers associated with RCP of coronary artery disease that could help to individualize the type and intensity of treatment.
Collapse
Affiliation(s)
- Tamara García-Camarero
- Departamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain.
| | | | - Fernanda Genre
- Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | | | | | - Gabriela Veiga
- Departamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | - Dae-Hyun Lee Hwang
- Departamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | - Fermín Sáinz Laso
- Departamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | - Aritz Gil Ongay
- Departamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| | - Miguel Ángel González-Gay
- Departamento de Medicina y Psiquiatría, Universidad de Cantabria, Santander, Cantabria, Spain; Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain
| | - José M de la Torre Hernández
- Departamento de Cardiología, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Valdecilla, Santander, Cantabria, Spain
| |
Collapse
|
5
|
Cruz-Utrilla A, Gallego-Zazo N, Pérez-Olivares C, Hernández-González I, Bedate P, Martínez Meñaca A, López Meseguer M, Lapunzina P, Pérez Núñez M, Ochoa Parra N, Valverde D, Tenorio-Castaño JA, Escribano-Subias P. Usefulness of genetics for clinical reclassification and refinement of prognostic stratification in pulmonary arterial hypertension. Rev Esp Cardiol (Engl Ed) 2023; 76:460-467. [PMID: 36403940 DOI: 10.1016/j.rec.2022.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 11/07/2022] [Indexed: 05/28/2023]
Abstract
INTRODUCTION AND OBJECTIVES Risk stratification in pulmonary arterial hypertension (PAH) is essential to provide more aggressive treatment for patients at higher risk. Nevertheless, recently introduced simplified prognostic tools neglect the genetic background. Additionally, pulmonary veno-oclusive disease (PVOD) has never been considered in risk assessment strategies. METHODS We analyzed consecutive patients in the Spanish registry of PAH (REHAP) genetically tested, between 2011 and 2022. We applied the 4-strata COMPERA 2.0 model, comparing these results with an amplified score including genetics. Cox regression models were compared using Harrel c-statistics. The application of the model was specifically tested in PVOD before inclusion. RESULTS We identified 298 patients tested genetically among the group of idiopathic, familial, drug-induced PAH and PVOD patients in the REHAP registry. When we analyzed only patients with all available variables of interest at baseline (World Health Organization functional class, 6-minute walk test, B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide) and included in the 4-strata model (n=142), after a median follow-up of 58.2 months, 17.6% of patients died and 11.3% underwent lung transplant. The application of the 4-strata model in our population demonstrated a good prognostic capacity (Harrel c of 0.689), which was not improved by the introduction of genetics (c-index 0.690). This last model showed a tendency for a better identification of patients at intermediate-low and intermediate-high risk, and no differences between intermediate-high and high-risk strata. CONCLUSIONS In this work, the addition of genetics to the COMPERA 4-strata model achieved a similar global prognostic capacity but changed the identification of different risk strata in a cohort of young genetically tested patients.
Collapse
Affiliation(s)
- Alejandro Cruz-Utrilla
- Unidad de Hipertensión Pulmonar, Departamento de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain; European Reference Network on rare respiratory diseases (ERN-LUNG), Belgium
| | - Natalia Gallego-Zazo
- Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain; European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ITHACA), Belgium
| | | | - Ignacio Hernández-González
- Cardiología Pediátrica, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - Pedro Bedate
- Departamento de Medicina Pulmonar, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - Amaya Martínez Meñaca
- European Reference Network on rare respiratory diseases (ERN-LUNG), Belgium; Departamento de Medicina Pulmonar, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Manuel López Meseguer
- European Reference Network on rare respiratory diseases (ERN-LUNG), Belgium; Departamento de Medicina Pulmonar, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Pablo Lapunzina
- Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain; European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ITHACA), Belgium
| | - Marta Pérez Núñez
- Departamento de Radiología, Unidad de Hipertensión Pulmonar, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Nuria Ochoa Parra
- Unidad de Hipertensión Pulmonar, Departamento de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain; European Reference Network on rare respiratory diseases (ERN-LUNG), Belgium
| | - Diana Valverde
- CINBIO, Instituto de Investigación Sanitaria Galicia Sur, Área de Enfermedades Raras y Medicina Pediátrica, Universidad de Vigo, Vigo, Spain
| | - Jair Antonio Tenorio-Castaño
- Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz, Madrid, Spain; Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain; European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ITHACA), Belgium
| | - Pilar Escribano-Subias
- Unidad de Hipertensión Pulmonar, Departamento de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain; European Reference Network on rare respiratory diseases (ERN-LUNG), Belgium; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
| |
Collapse
|
6
|
Ortega Suero G, Abenza Abildúa MJ, Serrano Munuera C, Rouco Axpe I, Arpa Gutiérrez FJ, Adarmes Gómez AD, Rodríguez de Rivera FJ, Quintans Castro B, Posada Rodríguez I, Vadillo Bermejo A, Domingo Santos Á, Blanco Vicente E, Infante Ceberio I, Pardo Fernández J, Costa Arpín E, Painous Martí C, Muñoz JE, Mir Rivera P, Montón Álvarez F, Bataller Alberola L, Gascón Bayarri J, Casasnovas Pons C, Vélez Santamaría V, López de Munain A, Fernández-Eulate G, Gazulla Abío J, Sanz Gallego I, Rojas Bartolomé L, Ayo Martín Ó, Segura Martín T, González Mingot C, Baraldés Rovira M, Sivera Mascaró R, Cubo Delgado E, Echavarría Íñiguez A, Vázquez Sánchez F, Bártulos Iglesias M, Casadevall Codina MT, Martínez Fernández EM, Labandeira Guerra C, Alemany Perna B, Carvajal Hernández A, Fernández Moreno C, Palacín Larroy M, Caballol Pons N, Ávila Rivera A, Navacerrada Barrero FJ, Lobato Rodríguez R, Sobrido Gómez MJ. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study. Neurologia 2023:S2173-5808(23)00023-8. [PMID: 37120112 DOI: 10.1016/j.nrleng.2023.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 01/01/2021] [Indexed: 05/01/2023] Open
Abstract
INTRODUCTION Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019. PATIENTS AND METHODS We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019. RESULTS We gathered data from a total of 1933 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 982 patients were men (50.8%) and 951 were women (49.2%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7. CONCLUSIONS In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials.
Collapse
Affiliation(s)
- G Ortega Suero
- Servicio de Neurología, Hospital Alcázar de San Juan, Complejo La Mancha-Centro, Ciudad Real, Spain
| | - M J Abenza Abildúa
- Servicio de Neurología, Hospital Universitario Infanta Sofía, Madrid, Spain.
| | | | - I Rouco Axpe
- Servicio de Neurología, Hospital Universitario de Cruces, Bilbao, Spain
| | - F J Arpa Gutiérrez
- Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Asesoría Docente de Neurología, Hospital Clínico San Carlos, Madrid, Spain
| | - A D Adarmes Gómez
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | - B Quintans Castro
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
| | - I Posada Rodríguez
- Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A Vadillo Bermejo
- Servicio de Neurología, Hospital Universitario Mancha Centro, Ciudad Real, Spain
| | - Á Domingo Santos
- Servicio de Neurología, Hospital G. Tomelloso, Ciudad Real, Spain
| | | | - I Infante Ceberio
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain
| | - J Pardo Fernández
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, Spain
| | - E Costa Arpín
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, Spain
| | - C Painous Martí
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, Spain
| | - J E Muñoz
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, Spain
| | - P Mir Rivera
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - F Montón Álvarez
- Servicio de Neurología, Hospital Nuestra señora de Candelaria, Tenerife, Spain
| | | | - J Gascón Bayarri
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, Spain
| | - C Casasnovas Pons
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, Spain
| | - V Vélez Santamaría
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, Spain
| | - A López de Munain
- Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain
| | - G Fernández-Eulate
- Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain
| | - J Gazulla Abío
- Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - I Sanz Gallego
- Servicio de Neurología, Hospital Universitario Sonsoles, Ávila, Spain
| | - L Rojas Bartolomé
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, Spain
| | - Ó Ayo Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, Spain
| | - T Segura Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, Spain
| | - C González Mingot
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | - M Baraldés Rovira
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | - R Sivera Mascaró
- Servicio de Neurología, Hospital Francesc de Borja, Gandía, Spain
| | - E Cubo Delgado
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, Spain
| | | | - F Vázquez Sánchez
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, Spain
| | | | | | | | - C Labandeira Guerra
- Servicio de Neurología, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain
| | - B Alemany Perna
- Servicio de Neurología, Hospital Universitario Josep Trueta, Girona, Spain
| | - A Carvajal Hernández
- Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | | | | | - N Caballol Pons
- Sección de Neurología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain
| | - A Ávila Rivera
- Servicio de Neurología, Hospital General L´Hospitalet, Barcelona, Spain
| | | | - R Lobato Rodríguez
- Sección de Neurología, Hospital Universitario Infanta Sofía, Madrid, Spain
| | | |
Collapse
|
7
|
Espinosa Cabello M, Ansio Vázquez I, Espejo Portero I, Rodriguez Fuentes D, Rabasco Ruiz C, Espinosa Hernández M. The natural history of autosomal dominant polycystic kidney disease. A strategy for grouping families and mutations. Nefrologia 2023; 43:120-125. [PMID: 37268502 DOI: 10.1016/j.nefroe.2023.03.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 05/17/2022] [Indexed: 06/04/2023] Open
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is a main cause of end-stage renal disease. Today, knowledge of its genetic basis has made it possible to develop strategies that prevent the transmission of the disease. OBJECTIVES The objective of the study was to analyze the natural history of ADPKD in the province of Córdoba and to design a database that allows grouping families with different mutations. PATIENTS AND METHODS All patients (n = 678) diagnosed with ADPKD followed by the Córdoba nephrology service are included. Various clinical variables (age and sex), genetic variables (mutation in PKD1, PKD2) and the need for renal replacement therapy (RRT) were retrospectively analyzed. RESULTS The prevalence was 61 cases per 100,000 inhabitants. Median renal survival was significantly worse in PKD1 (57.5 years) than in PKD2 (70 years) (log-rank p = 0.000). We have genetically identified 43.8% of the population, detecting PKD1 mutations in 61.2% and PKD2 mutations in 37.4% of cases, respectively. The most frequent mutation, in PKD2 (c.2159del), appeared in 68 patients belonging to 10 different families. The one with the worst renal prognosis was a truncating mutation in PKD1 (c.9893 G > A). These patients required RRT at a median age of 38.7 years. CONCLUSIONS Renal survival of ADPKD in the province of Córdoba is similar to that described in the literature. We detected PKD2 mutations in 37.4% of cases. This strategy allows us to know the genetic basis of a large proportion of our population while saving resources. This is essential to be able to offer primary prevention of ADPKD through preimplantation genetic diagnosis.
Collapse
Affiliation(s)
| | | | - Isabel Espejo Portero
- UGC de Análisis Clínicos, Genética-Molecular, Hospital Universitario Reina Sofía. Córdoba, Spain
| | | | | | | |
Collapse
|
8
|
Gómez-Pinedo U, Torre-Fuentes L, Matías-Guiu JA, Pytel V, Ojeda-Hernández DD, Selma-Calvo B, Montero-Escribano P, Vidorreta-Ballesteros L, Matías-Guiu J. Exonic variants of the P2RX7 gene in familial multiple sclerosis. Neurologia 2022:S2173-5808(22)00189-4. [PMID: 36470550 DOI: 10.1016/j.nrleng.2022.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Accepted: 10/09/2022] [Indexed: 12/12/2022] Open
Abstract
INTRODUCTION Several studies have analysed the presence of P2RX7 variants in patients with MS, reporting diverging results. METHODS Our study analyses P2RX7 variants detected through whole-exome sequencing (WES). RESULTS We analysed P2RX7, P2RX4, and CAMKK2 gene variants detected by whole-exome sequencing in all living members (n = 127) of 21 families including at least 2 individuals with multiple sclerosis. P2RX7 gene polymorphisms previously associated with autoimmune disease. Although no differences were observed between individuals with and without multiple sclerosis, we found greater polymorphism of gain-of-function variants of P2RX7 in families with individuals with multiple sclerosis than in the general population. Copresence of gain-of-function and loss-of-function variants was not observed to reduce the risk of presenting the disease. Three families displayed heterozygous gain-of-function SNPs in patients with multiple sclerosis but not in healthy individuals. We were unable to determine the impact of copresence of P2RX4 and CAMKK2 variants with P2RX7 variants, or the potential effect of the different haplotypes described in the gene. No clinical correlations with other autoimmune diseases were observed in our cohort. CONCLUSIONS Our results support the hypothesis that the disease is polygenic and point to a previously unknown mechanism of genetic predisposition to familial forms of multiple sclerosis. P2RX7 gene activity can be modified, which suggests the possibility of preventive pharmacological treatments for families including patients with familial multiple sclerosis.
Collapse
Affiliation(s)
- U Gómez-Pinedo
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.
| | - L Torre-Fuentes
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - J A Matías-Guiu
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - V Pytel
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain; Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - D D Ojeda-Hernández
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - B Selma-Calvo
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - P Montero-Escribano
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - L Vidorreta-Ballesteros
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - J Matías-Guiu
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain; Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
9
|
Juárez-Melchor D, Munguía-Realpozo P, Mendoza-Pinto C, Etchegaray-Morales I, Ayón-Aguilar J, Mendez-Martínez S, García-Carrasco M, Granados Arriola J. Genetic component of autoimmune rheumatological diseases. Reumatol Clin (Engl Ed) 2022; 18:614-620. [PMID: 34953732 DOI: 10.1016/j.reumae.2021.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/27/2021] [Accepted: 08/02/2021] [Indexed: 06/14/2023]
Abstract
The purpose of this review is to present the main aspects of the genetic component of autoimmune rheumatic diseases, including the characteristics of the multifactorial or polygenic inheritance model, and its monogenic forms, as well as the main associated genes in both cases. The epigenetic changes involved, and the influence of the environment and sex that confer greater risk to women suffering from any of these diseases. Finally, to make known the advances that the study of omic sciences has allowed, opening the way to a new molecular classification of these diseases, aimed at personalized medicine. A review of the literature of the last 5 years, of English-language publications, in the PubMed database was performed and 28 review articles, and 19 original articles were included. Knowledge of the genetic factors involved in the aetiology of autoimmune rheumatic diseases, thanks to the availability of molecular studies, allows a better understanding of their pathophysiology and the possibility of diagnosis and treatment based on molecular markers in the future.
Collapse
Affiliation(s)
- Daniela Juárez-Melchor
- Departamento de Genética, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico; Departamento de Genética, Instituto Mexicano del Seguro Social, Puebla, Mexico
| | - Pamela Munguía-Realpozo
- Departamento de Reumatología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - Claudia Mendoza-Pinto
- Departamento de Reumatología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico; Unidad de Investigación de Enfermedades Autoinmunes Sistémicas, CIBIOR-Hospital de Especialidades UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico
| | - Ivet Etchegaray-Morales
- Departamento de Reumatología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - Jorge Ayón-Aguilar
- Coordinador Médico de Investigación en Salud, Instituto Mexicano del Seguro Social, Delegación Puebla, Mexico
| | - Socorro Mendez-Martínez
- Coordinación de Planeación y Enlace Institucional, Instituto Mexicano del Seguro Social, Delegación Puebla, Mexico
| | - Mario García-Carrasco
- Departamento de Reumatología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
| | - Julio Granados Arriola
- División de Inmunogenética, Departamento de Trasplantes, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| |
Collapse
|
10
|
Santos Simarro F. Advances in clinical genetics and its current challenges. An Pediatr (Barc) 2022; 97:281.e1-281.e5. [PMID: 36115780 DOI: 10.1016/j.anpede.2022.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 08/30/2022] [Indexed: 11/27/2022] Open
Abstract
The great advances in the development of genomic technologies and their incorporation into routine clinical practice is bringing about a change in which an individual's genetic information is becoming increasingly relevant to their medical care. This is known as genomic medicine. Its implementation is not without barriers, including difficulties in the assessment and interpretation of genomic data, deficient training of professionals and patients in this field, unequal access to units with expertise, and a lack of professional profiles and infrastructures necessary for the incorporation of genomic technologies into routine clinical practice. This article reviews the advances and challenges of genomic medicine.
Collapse
Affiliation(s)
- Fernando Santos Simarro
- Unidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
| |
Collapse
|
11
|
Gomez-Pinedo U, Matías-Guiu JA, Torre-Fuentes L, Montero-Escribano P, Hernández-Lorenzo L, Pytel V, Maietta P, Alvarez S, Sanclemente-Alamán I, Moreno-Jimenez L, Ojeda-Hernandez D, Villar-Gómez N, Benito-Martin MS, Selma-Calvo B, Vidorreta-Ballesteros L, Madrid R, Matías-Guiu J. Variant rs4149584 (R92Q) of the TNFRSF1A gene in patients with familial multiple sclerosis. Neurologia 2022:S2173-5808(22)00087-6. [PMID: 35963536 DOI: 10.1016/j.nrleng.2022.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Accepted: 07/15/2022] [Indexed: 11/26/2022] Open
Abstract
INTRODUCTION Genomic studies have identified numerous genetic variants associated with susceptibility to multiple sclerosis (MS); however, each one explains only a small percentage of the risk of developing the disease. These variants are located in genes involved in specific pathways, which supports the hypothesis that the risk of developing MS may be linked to alterations in these pathways, rather than in specific genes. We analyzed the role of the TNFRSF1A gene, which encodes one of the TNF-α receptors involved in a signaling pathway previously linked to autoimmune disease. METHODS We included 138 individuals from 23 families including at least 2 members with MS, and analyzed the presence of exonic variants of TNFRSF1A through whole-exome sequencing. We also conducted a functional study to analyze the pathogenic mechanism of variant rs4149584 (-g.6442643C > G, NM_001065.4:c.362 G > A, R92Q) by plasmid transfection into human oligodendroglioma (HOG) cells, which behave like oligodendrocyte lineage cells; protein labeling was used to locate the protein within cells. We also analyzed the ability of transfected HOG cells to proliferate and differentiate into oligodendrocytes. RESULTS Variant rs4149584 was found in 2 patients with MS (3.85%), one patient with another autoimmune disease (7.6%), and in 5 unaffected individuals (7.46%). The 2 patients with MS and variant rs4149584 were homozygous carriers and belonged to the same family, whereas the remaining individuals presented the variant in heterozygosis. The study of HOG cells transfected with the mutation showed that the protein does not reach the cell membrane, but rather accumulates in the cytoplasm, particularly in the endoplasmic reticulum and near the nucleus; this suggests that, in the cells presenting the mutation, TNFRSF1 does not act as a transmembrane protein, which may alter its signaling pathway. The study of cell proliferation and differentiation found that transfected cells continue to be able to differentiate into oligodendrocytes and are probably still capable of producing myelin, although they present a lower rate of proliferation than wild-type cells. CONCLUSIONS Variant rs4149584 is associated with risk of developing MS. We analyzed its functional role in oligodendrocyte lineage cells and found an association with MS in homozygous carriers. However, the associated molecular alterations do not influence the differentiation into oligodendrocytes; we were therefore unable to confirm whether this variant alone is pathogenic in MS, at least in heterozygosis.
Collapse
Affiliation(s)
- U Gomez-Pinedo
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain.
| | - J A Matías-Guiu
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - L Torre-Fuentes
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - P Montero-Escribano
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - L Hernández-Lorenzo
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - V Pytel
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain; Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | | | | | - I Sanclemente-Alamán
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - L Moreno-Jimenez
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - D Ojeda-Hernandez
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - N Villar-Gómez
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - M S Benito-Martin
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - B Selma-Calvo
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | - L Vidorreta-Ballesteros
- Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| | | | - J Matías-Guiu
- Laboratory of Neurobiology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain; Department of Neurology, Institute of Neurosciences, IdISSC, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
12
|
Rodríguez-Toscano E, Martínez K, Fraguas D, Janssen J, Pina-Camacho L, Arias B, Vieta E, Mezquida G, Amoretti S, Bernardo M, Castro-Fornieles J, Cuesta-Zorita MJ, Lobo A, González-Pinto A, Collado IC, Mané A, Arango C, Parellada M. Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val 158Met polymorphism in first episode psychosis. Rev Psiquiatr Salud Ment (Engl Ed) 2022; 15:74-87. [PMID: 35840287 DOI: 10.1016/j.rpsmen.2022.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 11/06/2021] [Indexed: 06/15/2023]
Abstract
INTRODUCTION Core dysfunctions proposed for psychotic disorders include prefrontal cortex (PFC) dopaminergic hypoactivity, executive function (EF) deficits and reduced gray matter in the PFC. The Val variant of COMT Val158Met polymorphism is associated with reduced dopaminergic signaling in the PFC. However, it is unclear how COMT Val158Met modulates PFC gray matter reduction, EF deficits and symptom severity at the time of the first psychotic episode. METHODS The effect of COMT on both EF performance and prefrontal volume (PFC-VOL) was tested in 158 first episode psychosis (FEP) patients and 141 healthy controls (HC) matched for age (range 9-35 years), sex, ethnicity, handedness and COMT Val158Met distribution. EF and PFC-VOL were compared between FEP and HC groups within each polymorphism status (Met/Met versus Val carriers) to assess whether COMT influenced diagnostic differences. Next, correlations between PFC-VOL and EF performance were computed, as well as between both variables and other clinical characteristics of interest (PANSS scores, PAS infancy and premorbid IQ) in the FEP sample. RESULTS COMT influenced the diagnostic differences mainly in PFC-VOL, but also in EF performance. FEP-Val carriers showed lower EF scores and reduced PFC-VOL compared to the HC group but also poorer EF performance than FEP Met/Met. Poorer EF performance was associated with smaller PFC-VOL, and both were related to increased severity of negative symptoms, poorer premorbid adjustment, and lower estimated premorbid IQ in FEP patients. CONCLUSIONS Our findings suggest that COMT Val158Met polymorphism might contribute to PFC-VOL reductions, executive dysfunctions and symptom severity in FEP patients.
Collapse
Affiliation(s)
- Elisa Rodríguez-Toscano
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Experimental Psychology, Cognitive Psychology and Speech & Language Therapy Immunology, Faculty of Psychology, Universidad Complutense Madrid, Spain.
| | - Kenia Martínez
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Ciber del Area de Salud Mental (CIBERSAM), Spain
| | - David Fraguas
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Ciber del Area de Salud Mental (CIBERSAM), Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| | - Joost Janssen
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Ciber del Area de Salud Mental (CIBERSAM), Spain
| | - Laura Pina-Camacho
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Ciber del Area de Salud Mental (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, UK
| | - Bárbara Arias
- Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, CIBERSAM, Barcelona, Spain
| | - Eduard Vieta
- Ciber del Area de Salud Mental (CIBERSAM), Spain; Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
| | - Gisela Mezquida
- Ciber del Area de Salud Mental (CIBERSAM), Spain; Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Spain; Department of Medicine, Institut de Neurociències, Universitat de Barcelona, Spain
| | - Silvia Amoretti
- Ciber del Area de Salud Mental (CIBERSAM), Spain; Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Spain; Department of Medicine, Institut de Neurociències, Universitat de Barcelona, Spain
| | - Miguel Bernardo
- Ciber del Area de Salud Mental (CIBERSAM), Spain; Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; Barcelona Clinic Schizophrenia Unit, Hospital Clinic of Barcelona, Neuroscience Institute, Spain; Department of Medicine, Institut de Neurociències, Universitat de Barcelona, Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Spain
| | - Josefina Castro-Fornieles
- Department of Child and Adolescent Psychiatry and Psychology, Clínic Institute of Neurosciences, Hospital Clínic de Barcelona, 2017SGR881, University of Barcelona, CIBERSAM, IDIBAPS, Barcelona, Spain
| | - Manuel Jesús Cuesta-Zorita
- Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain
| | - Antonio Lobo
- Department of Medicine and Psychiatry, Zaragoza University, Spain; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, CIBERSAM, Madrid, Spain
| | - Ana González-Pinto
- Ciber del Area de Salud Mental (CIBERSAM), Spain; Department of Psychiatry, Araba University Hospital, Bioaraba Research Institute, Department of Neurociences, University of the Basque Country, Vitoria, Spain
| | - Iluminada Corripio Collado
- Department of Psychiatry, Sant Pau Hospital, Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Barcelona, Spain
| | - Anna Mané
- Ciber del Area de Salud Mental (CIBERSAM), Spain; Hospital del Mar Medical Research Institute (IMIM), Spain; Autonomous University of Barcelona, Spain
| | - Celso Arango
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Ciber del Area de Salud Mental (CIBERSAM), Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| | - Mara Parellada
- Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain; Ciber del Area de Salud Mental (CIBERSAM), Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| |
Collapse
|
13
|
Cobo J, Coronas R, Pousa E, Oliva JC, Giménez-Palop O, Caixàs A. An adapted scale to evaluate insight in Prader-Willi Syndrome. Med Clin (Barc) 2021; 159:130-133. [PMID: 34696903 DOI: 10.1016/j.medcli.2021.07.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 07/03/2021] [Accepted: 07/05/2021] [Indexed: 02/04/2023]
Abstract
OBJECTIVE To develop an insight scale for Prader-Willi Syndrome (PWS), a genetically determined neurodevelopmental disorder with different psychopathological and behavioural problems. METHODOLOGY A sample of 36 PWS patients (58.3% women) attended at the Endocrinological Department of the Corporació Sanitària Parc Taulí (Sabadell, Barcelona) was evaluated. Insight was assessed by means of an adapted version of the Scale of Unawareness of Mental Disorder (SUMD), including three general insight dimensions: awareness of having a PWS, awareness of the effects of psychopharmacological medication and awareness of the social consequences, as well as three items that assess awareness of each particular symptom of the disease (obesity/overweight, excessive appetite and excessive food intake). RESULTS The final Scale included six items and demonstrated an adequate internal consistency (Cronbach Alfa of 0.857 for Caregivers and 0.798 for Clinicians) but a high inter-rate variability. External validation using an Analytical-Visual Insight Scale was adequate. CONCLUSIONS The Adapted version for Prader-Willi patients of the Scale of Unawareness of Mental Disorder (APW-SUD) showed adequate psychometric properties and it is an easy to administer means to assess insight in this population.
Collapse
Affiliation(s)
- Jesus Cobo
- Mental Health Department, Corporació Sanitària Parc Taulí - Universitat Autònoma de Barcelona - Institut d'Investigació i Innovació Parc Taulí (I3PT), CIBERSAM, Sabadell, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; Insight Barcelona Research Group, Societat Catalana de Psiquiatria i Salut Mental, Barcelona, Spain.
| | - Ramón Coronas
- Mental Health Department, Corporació Sanitària Parc Taulí - Universitat Autònoma de Barcelona - Institut d'Investigació i Innovació Parc Taulí (I3PT), CIBERSAM, Sabadell, Spain
| | - Esther Pousa
- Insight Barcelona Research Group, Societat Catalana de Psiquiatria i Salut Mental, Barcelona, Spain; Psychiatry Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - Joan-Carles Oliva
- Statistic Unit, Institut d'Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain
| | - Olga Giménez-Palop
- Endocrinology and Nutrition Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT), Medicine Department, Universitat Autònoma de Barcelona, Sabadell, Spain
| | - Assumpta Caixàs
- Endocrinology and Nutrition Department, Hospital Universitari Parc Taulí, Institut d'Investigació i Innovació Parc Taulí (I3PT), Medicine Department, Universitat Autònoma de Barcelona, Sabadell, Spain
| |
Collapse
|
14
|
Nóvoa-Medina Y, Domínguez García A, Quinteiro González S, García Cruz LM, Santana Rodríguez A. Congenital hyperinsulinism in Gran Canaria, Canary Isles. An Pediatr (Barc) 2021; 95:93-100. [PMID: 34253504 DOI: 10.1016/j.anpede.2020.08.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 08/31/2020] [Indexed: 10/20/2022] Open
Abstract
INTRODUCTION Congenital hyperinsulinism (CH) is a severe disorder characterised by the appearance of severe hypoglycaemia. Pathogenic mutations in the ABCC8 and KCNJ11 genes are the most frequent cause, although its appearance also been associated to mutations in other genes (GCK, GLUD1, HADH, HNF1A, HNF4A, SLC16A1, UCP2, HK1), and with different syndromes. MATERIALS AND METHODS Retrospective review of patients diagnosed with CH in this unit during the last 18 years (2001-2018). Genetic analysis included screening for 11 genes in genomic DNA from peripheral blood (ABCC8, GCK, GLUD1, HADH, HNF1A, HNF4A, INSR, KCNJ11, SLC16A1, UCP2, and SLC25A15). OBJECTIVE To carry out a clinical and genetic characterisation of the diagnosed cases of CH in Gran Canaria. RESULTS There have been 10 cases of persistent HC since 2001. Seven of them had mutations in the ABCC8 gene, one in the HNF4α gene, and in two patients, no pathogenic mutations were found in the analysed genes. Four patients presented with previously undescribed mutations. Pancreatectomy was performed in two of the cases. The minimum insulin value detected in hypoglycaemia was 6.81 µIU/mL. The incidence of persistent CH for Gran Canaria and Lanzarote is 1/15,614. CONCLUSIONS Four patients had previously undescribed mutations. The most frequently affected gene was ABCC8. Pancreatectomy was required in 20% of the patients. An insulin value of ≥6.81 µIU/mL was observed in all patients at the time of diagnosis. The incidence of CH in Gran Canaria is high.
Collapse
Affiliation(s)
- Yeray Nóvoa-Medina
- Unidad de Endocrinología Pediátrica, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain; Asociación Canaria para la Investigación Pediátrica (ACIP Canarias), Las Palmas de Gran Canaria, Spain.
| | - Angela Domínguez García
- Unidad de Endocrinología Pediátrica, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain
| | - Sofía Quinteiro González
- Unidad de Endocrinología Pediátrica, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain
| | - Loida María García Cruz
- Unidad de Genética Clínica, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain
| | - Alfredo Santana Rodríguez
- Unidad de Genética Clínica, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Spain
| |
Collapse
|
15
|
Orois A, Mora M, Halperin I, Oriola J. Familial non medullary thyroid carcinoma: Beyond the syndromic forms. ENDOCRINOL DIAB NUTR 2021; 68:260-269. [PMID: 34266638 DOI: 10.1016/j.endien.2020.08.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 08/17/2020] [Indexed: 10/20/2022]
Abstract
Familial non-medullary thyroid cancer is defined as the presence of non-medullary thyroid cancer in two or more first-degree relatives, in the absence of other predisposing factors. It represents up to 9% of differentiated thyroid cancers, and only a minority appears in well-known hereditary syndromes that associate thyroid cancer among many other clinical manifestations. However, in more than 95% of cases, thyroid cancer appears isolated, and its genetic causes have yet to be elucidated. We review here the current knowledge of the genetic basis of this pathology, as well as its clinical characteristics. Understanding the genetic mechanisms implied would help to comprehend the metabolic pathways involved, with the consequent potential therapeutic application. In addition, it would allow genetic counseling and to focus our efforts on patients at risk of developing this disorder.
Collapse
Affiliation(s)
- Aida Orois
- Servicio de Endocrinología y Nutrición, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain; Servicio de Endocrinología y Nutrición, ICMDM, Hospital Clínic de Barcelona, Barcelona, Spain.
| | - Mireia Mora
- Servicio de Endocrinología y Nutrición, ICMDM, Hospital Clínic de Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Facultad de Medicina, Universidad de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - Irene Halperin
- Servicio de Endocrinología y Nutrición, ICMDM, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Josep Oriola
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Facultad de Medicina, Universidad de Barcelona, Barcelona, Spain; Servicio de Bioquímica y Genética Molecular, CDB, Hospital Clínic de Barcelona, Barcelona, Spain
| |
Collapse
|
16
|
Arrobas Velilla T, Brea Á, Valdivielso P. Implantation of a biochemical and genetic screening programme for family hypercholesterolaemia. Collaboration between the clinical laboratory and lipid units: Design of the ARIAN Project. Clin Investig Arterioscler 2021; 33:289-295. [PMID: 34090714 DOI: 10.1016/j.arteri.2021.03.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 03/17/2021] [Accepted: 03/23/2021] [Indexed: 02/04/2023]
Abstract
INTRODUCTION AND OBJECTIVE Familial hypercholesterolaemia (FH) is the most common genetic disorder associated with premature coronary artery disease due to the presence of LDL-C cholesterol increased from birth. It is underdiagnosed and undertreated. The primary objective of the ARIAN project was to determine the number of patients diagnosed with FH after implementing a new screening procedure from the laboratory. MATERIAL AND METHODS This project was designed as a retrospective analysis by consulting the computer system. We selected from databases serum samples from patients ≥ 18 years with direct or calculated LDL-C>250mg/dL from 1 January 2017 to 31 December 2018. Once secondary causes had been ruled out, the requesting primary care physician was notified that their patient might have FH and to arrange a priority appointment in the lipid unit. All patients with a score of ≥ 6 points according to the Dutch Lipid Clinic Criteria were proposed for a genetic study RESULTS: By December 30th, 2020, 24 centres out of the initial 55 had submitted results. The number of patients analysed up to that point was 3,266,341, which represents 34% of the population served in those health areas (9,727,434). CONCLUSIONS The identification of new subjects with FH through this new strategy from the laboratory and their referral to lipid units should increase the number of patients treated in lipid units and initiate familial cascade screening.
Collapse
Affiliation(s)
- Teresa Arrobas Velilla
- Laboratorio de Nutrición y Riesgo Cardiovascular de Bioquímica Clínica, Unidad de Lípidos, Hospital Universitario Virgen de la Macarena, Sevilla, España.
| | - Ángel Brea
- Servicio de Medicina Interna y Unidad de Lípidos, Hospital San Pedro, Logroño, La Rioja, España
| | - Pedro Valdivielso
- Servicio de Medicina Interna y Unidad de Lípidos, Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, Málaga, España
| | | | | |
Collapse
|
17
|
Ripoll-Vera T, Pérez Luengo C, Borondo Alcázar JC, García Ruiz AB, Sánchez Del Valle N, Barceló Martín B, Poncela García JL, Gutiérrez Buitrago G, Dasi Martínez C, Canós Villena JC, Moyano Corvillo S, Esgueva Pallarés R, Sancho Sancho JR, Guitart Pinedo G, Hernández Marín E, García García E, Vingut López A, Álvarez Rubio J, Govea Callizo N, Gómez Pérez Y, Melià Mesquida C, Heine D, Rosell Andreo J, Socías Crespí L. Sudden cardiac death in persons aged 50 years or younger: diagnostic yield of a regional molecular autopsy program using massive sequencing. Rev Esp Cardiol (Engl Ed) 2021; 74:402-413. [PMID: 32917565 DOI: 10.1016/j.rec.2020.03.030] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Accepted: 03/04/2020] [Indexed: 06/11/2023]
Abstract
INTRODUCTION AND OBJECTIVES Sudden cardiac death (SCD) in young people often has a genetic cause. Consequently, the results of "molecular autopsy" may have important implications for their relatives. Our objective was to evaluate the diagnostic yield of a molecular autopsy program using next-generation sequencing. METHODS We performed a prospective study of a cohort of consecutive patients who died from nonviolent SCD, aged ≤ 50 years, and who underwent molecular autopsy using large panels of next-generation sequencing, with subsequent clinical and genetic family screening. We analyzed demographic, clinical, toxicological, and genetic data. RESULTS We studied 123 consecutive cases of SCD in persons aged ≤ 50 years. The incidence of SCD was 5.8 cases/100 000 individuals/y, mean age was 36.15±12.7 years, and 95 were men (77%). The cause was cardiac in 53%, unexplained SCD in 24%, toxic in 10.6%, and infant SCD in 4%. Among cardiac causes, ischemic heart disease accounted for 38% of deaths, arrhythmogenic cardiomyopathy for 7%, hypertrophic cardiomyopathy for 5%, and idiopathic left ventricular hypertrophy for 11%. Genetic analysis was performed in 62 cases (50.4%). Genetic variants were found in 42 cases (67.7%), with a mean of 3.4±4 genetic variants/patient, and the variant found was considered to be pathogenic or probably pathogenic in 30.6%. In unexplained SCD, 70% showed some genetic variant. Family screening diagnosed 21 carriers or affected individuals, 5 of whom were at risk, indicating an implantable cardiac defibrillator. CONCLUSIONS Protocol-based and exhaustive study of SCD from cardiac causes in persons aged ≤ 50 years is feasible and necessary. In a high percentage of cases, the cause is genetic, indicating the existence of relatives at risk who could benefit from early diagnosis and treatment to avoid complications.
Collapse
Affiliation(s)
- Tomás Ripoll-Vera
- Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain; Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain.
| | - Consuelo Pérez Luengo
- Instituto de Medicina Legal de las Islas Baleares, Palma de Mallorca, Islas Baleares, Spain
| | | | - Ana Belén García Ruiz
- Instituto de Medicina Legal de las Islas Baleares, Palma de Mallorca, Islas Baleares, Spain
| | | | - Bernardino Barceló Martín
- Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain; Servicio de Análisis Clínicos y Toxicología, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain
| | | | | | - Concepción Dasi Martínez
- Servicio de Histopatología, Instituto Nacional de Toxicología y Ciencias Forenses, Barcelona, Spain
| | | | - Susana Moyano Corvillo
- Servicio de Histopatología, Instituto Nacional de Toxicología y Ciencias Forenses, Barcelona, Spain
| | - Raquel Esgueva Pallarés
- Servicio de Histopatología, Instituto Nacional de Toxicología y Ciencias Forenses, Barcelona, Spain
| | | | | | - Elena Hernández Marín
- Servicio de Química, Instituto Nacional de Toxicología y Ciencias Forenses, Barcelona, Spain
| | - Estela García García
- Servicio de Química, Instituto Nacional de Toxicología y Ciencias Forenses, Barcelona, Spain
| | - Albert Vingut López
- Servicio de Química, Instituto Nacional de Toxicología y Ciencias Forenses, Barcelona, Spain
| | - Jorge Álvarez Rubio
- Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain; Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain
| | - Nancy Govea Callizo
- Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain; Sección de Genética, Unidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain
| | - Yolanda Gómez Pérez
- Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain; Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain
| | - Catalina Melià Mesquida
- Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain; Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain
| | - Damián Heine
- Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain; Sección de Genética, Unidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain
| | - Jordi Rosell Andreo
- Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain; Sección de Genética, Unidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain
| | - Lorenzo Socías Crespí
- Instituto de Investigación Sanitaria de Baleares (IdISBa), Palma de Mallorca, Islas Baleares, Spain; Servicio de Medicina Intensiva, Hospital Universitario Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain
| |
Collapse
|
18
|
Ancira-Moreno M, Smith N, Lamadrid-Figueroa H. [Scope of Mendelian randomization to control for unobserved confounding in epidemiology]. Gac Sanit 2021; 36:274-277. [PMID: 33781616 DOI: 10.1016/j.gaceta.2021.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2020] [Revised: 01/28/2021] [Accepted: 01/29/2021] [Indexed: 11/04/2022]
Abstract
The Mendelian randomization is an epidemiologic method proposed to control for spurious associations in observational studies. These associations are commonly caused by confusion derived from social, environmental, and behavioral factors, which can be difficult to measure. Mendelian randomization is based on the selection of genetic variants that are used as instrumental variables that influence exposure patterns or are associated with an intermediate phenotype of the disease. The present work aims to discuss how to select the appropriate genetic variants as instrumental variables and to present methodological tools to deal with the limitations of this epidemiological method. The use of instrumental variables for modifiable exposures has the potential to mitigate the effects of common limitations, such as confusion, when robust genetic variants are chosen as instrumental variables.
Collapse
Affiliation(s)
| | - Natalia Smith
- Departamento de Salud, Universidad Iberoamericana, Ciudad de México, México
| | - Héctor Lamadrid-Figueroa
- Dirección de Salud Reproductiva, Centro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México.
| |
Collapse
|
19
|
Ortega Suero G, Abenza Abildúa MJ, Serrano Munuera C, Rouco Axpe I, Arpa Gutiérrez FJ, Adarmes Gómez AD, Rodríguez de Rivera FJ, Quintans Castro B, Posada Rodríguez I, Vadillo Bermejo A, Domingo Santos Á, Blanco Vicente E, Infante Ceberio I, Pardo Fernández J, Costa Arpín E, Painous Martí C, Muñoz JE, Mir Rivera P, Montón Álvarez F, Bataller Alberola L, Gascón Bayarri J, Casasnovas Pons C, Vélez Santamaría V, López Munain A, Fernández García Eulate G, Gazulla Abío J, Sanz Gallego I, Rojas Bartolomé L, Ayo Martín Ó, Segura Martín T, González Mingot C, Baraldés Rovira M, Sivera Mascaró R, Cubo Delgado E, Echevarría Íñiguez A, Vázquez Sánchez F, Bártulos Iglesias M, Casadevall Codina MT, Martínez Fernández EM, Labandeira Guerra C, Alemany Perna B, Carvajal Hernández A, Fernández Moreno C, Palacín Larroy M, Caballol Pons N, Ávila Rivera A, Navacerrada Barrero FJ, Lobato Rodríguez R, Sobrido Gómez MJ. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study. Neurologia 2021; 38:S0213-4853(21)00021-9. [PMID: 33775475 DOI: 10.1016/j.nrl.2021.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 01/01/2021] [Indexed: 10/21/2022] Open
Abstract
INTRODUCTION Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019. PATIENTS AND METHODS We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019. RESULTS We gathered data from a total of 1.809 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 920 patients were men (50.8%) and 889 were women (49.2%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7. CONCLUSIONS In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials.
Collapse
Affiliation(s)
- G Ortega Suero
- Servicio de Neurología, Hospital Alcázar de San Juan, Complejo La Mancha-Centro, Ciudad Real, España
| | - M J Abenza Abildúa
- Servicio de Neurología, Hospital Universitario Infanta Sofía, Madrid, España.
| | - C Serrano Munuera
- Servicio de Neurología, Hospital Sant Joan de Déu, Martorell, España
| | - I Rouco Axpe
- Servicio de Neurología, Hospital Universitario de Cruces, Bilbao, España
| | - F J Arpa Gutiérrez
- Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Asesoría Docente de Neurología, Hospital Clínico San Carlos, Madrid, España
| | - A D Adarmes Gómez
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - F J Rodríguez de Rivera
- Servicio de Neurología, Hospital Universitario La Paz-Carlos III-Cantoblanco, Madrid, España
| | - B Quintans Castro
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, España
| | - I Posada Rodríguez
- Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, España
| | - A Vadillo Bermejo
- Servicio de Neurología, Hospital Universitario Mancha Centro, Ciudad Real, España
| | - Á Domingo Santos
- Servicio de Neurología, Hospital G. Tomelloso, Ciudad Real, España
| | - E Blanco Vicente
- Servicio de Neurología, Hospital Villarrobledo, Albacete, España
| | - I Infante Ceberio
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Cantabria, España
| | - J Pardo Fernández
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, España
| | - E Costa Arpín
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, España
| | - C Painous Martí
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, España
| | - J E Muñoz
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, España
| | - P Mir Rivera
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - F Montón Álvarez
- Servicio de Neurología, Hospital Nuestra señora de Candelaria, Tenerife, España
| | | | - J Gascón Bayarri
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, España
| | - C Casasnovas Pons
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, España
| | - V Vélez Santamaría
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, España
| | - A López Munain
- Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, España
| | | | - J Gazulla Abío
- Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, España
| | - I Sanz Gallego
- Servicio de Neurología, Hospital Universitario Sonsoles, Ávila, España
| | - L Rojas Bartolomé
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, España
| | - Ó Ayo Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, España
| | - T Segura Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, España
| | - C González Mingot
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, España
| | - M Baraldés Rovira
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, España
| | - R Sivera Mascaró
- Servicio de Neurología, Hospital Francesc de Borja, Gandía, España
| | - E Cubo Delgado
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, España
| | | | - F Vázquez Sánchez
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, España
| | | | | | | | - C Labandeira Guerra
- Servicio de Neurología, Hospital Universitario Álvaro Cunqueiro, Vigo, España
| | - B Alemany Perna
- Servicio de Neurología, Hospital Universitario Josep Trueta, Girona, España
| | - A Carvajal Hernández
- Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Granada, España
| | | | | | - N Caballol Pons
- Sección de Neurología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, España
| | - A Ávila Rivera
- Servicio de Neurología, Hospital General ĹHospitalet, Barcelona, España
| | | | - R Lobato Rodríguez
- Sección de Neurología, Hospital Universitario Infanta Sofía, Madrid, España
| | | |
Collapse
|
20
|
Orois A, Mora M, Halperin I, Oriola J. Familial non medullary thyroid carcinoma: Beyond the syndromic forms. ACTA ACUST UNITED AC 2020; 68:260-269. [PMID: 33191196 DOI: 10.1016/j.endinu.2020.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 07/25/2020] [Accepted: 08/17/2020] [Indexed: 11/16/2022]
Abstract
Familial non-medullary thyroid cancer is defined as the presence of non-medullary thyroid cancer in two or more first-degree relatives, in the absence of other predisposing factors. It represents up to 9% of differentiated thyroid cancers, and only a minority appears in well-known hereditary syndromes that associate thyroid cancer among many other clinical manifestations. However, in more than 95% of cases, thyroid cancer appears isolated, and its genetic causes have yet to be elucidated. We review here the current knowledge of the genetic basis of this pathology, as well as its clinical characteristics. Understanding the genetic mechanisms implied would help to comprehend the metabolic pathways involved, with the consequent potential therapeutic application. In addition, it would allow genetic counseling and to focus our efforts on patients at risk of developing this disorder.
Collapse
Affiliation(s)
- Aida Orois
- Servicio de Endocrinología y Nutrición, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, España; Servicio de Endocrinología y Nutrición, ICMDM, Hospital Clínic de Barcelona, Barcelona, España.
| | - Mireia Mora
- Servicio de Endocrinología y Nutrición, ICMDM, Hospital Clínic de Barcelona, Barcelona, España; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España; Facultad de Medicina, Universidad de Barcelona, Barcelona, España; Centro de Investigación Biomédica en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, España
| | - Irene Halperin
- Servicio de Endocrinología y Nutrición, ICMDM, Hospital Clínic de Barcelona, Barcelona, España
| | - Josep Oriola
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España; Facultad de Medicina, Universidad de Barcelona, Barcelona, España; Servicio de Bioquímica y Genética Molecular, CDB, Hospital Clínic de Barcelona, Barcelona, España
| |
Collapse
|
21
|
Navarro S, Cuatrecasas M, Hernández-Losa J, Landolfi S, Musulén E, Ramón Y Cajal S, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, García-Alfonso P. [Update of the recommendations for the determination of biomarkers in colorectal carcinoma. National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology]. Rev Esp Patol 2020; 54:41-54. [PMID: 33455693 DOI: 10.1016/j.patol.2020.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 07/02/2020] [Accepted: 07/26/2020] [Indexed: 11/25/2022]
Abstract
This update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica - SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica - SEAP), reviews the advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC. Recently published information on the essential determination of KRAS, NRAS and BRAF mutations and the possible benefits of determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated. From a pathological point of view, the importance of analysing the tumour budding and poorly differentiated clusters and its prognostic value in CRC is reviewed, as well as the impact of molecular lymph node analysis on lymph node staging in CRC. The incorporation of pan-genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy in the clinical management of patients with CRC is also outlined. All these aspects are developed in this guide which, like the previous one, will be revised when necessary in the future.
Collapse
Affiliation(s)
- Samuel Navarro
- Departamento de Patología, Universidad de Valencia, Hospital Clínico Universitario de Valencia, CIBERONC, Valencia, España.
| | | | - Javier Hernández-Losa
- Departamento de Patología, Hospital Universitario Vall d'Hebron, CIBERONC, Barcelona, España
| | - Stefania Landolfi
- Departamento de Patología, Hospital Universitario Vall d'Hebron, CIBERONC, Barcelona, España
| | - Eva Musulén
- Departamento de Patología, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Vallès, España; Grupo de Epigenética del Cáncer, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, España
| | - Santiago Ramón Y Cajal
- Departamento de Patología, Hospital Universitario Vall d'Hebron, CIBERONC, Barcelona, España
| | - Rocío García-Carbonero
- Departamento de Oncología Médica, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, España
| | - Jesús García-Foncillas
- Departamento de Oncología, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, España
| | - Pedro Pérez-Segura
- Departamento de Oncología Médica, Hospital Clínico Universitario San Carlos, CIBERONC, Madrid, España
| | - Ramón Salazar
- Departamento de Oncología Médica, ICO ĹHospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, España
| | - Ruth Vera
- Departamento de Oncología Médica, Complejo Hospitalario de Navarra, Navarrabiomed, IDISNA, Pamplona, España
| | - Pilar García-Alfonso
- Departamento de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, España
| |
Collapse
|
22
|
Díaz-Peña R, Silva RS, Hosgood HD, Jaime S, Miravitlles M, Olloquequi J. HLA-DRB1 Alleles are Associated With COPD in a Latin American Admixed Population. Arch Bronconeumol 2020; 57:291-297. [PMID: 32948369 DOI: 10.1016/j.arbres.2020.07.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 06/19/2020] [Accepted: 07/17/2020] [Indexed: 10/23/2022]
Abstract
INTRODUCTION While the molecular mechanisms of COPD pathogenesis remain obscure, there is mounting evidence supporting a key role for autoimmunity. Although human leukocyte antigens (HLA) alleles have been repeatedly associated with autoimmune processes, the relation between HLA and COPD remains largely unexplored, especially in Latin American (LA) populations. Consequently, this study aimed to investigate the presence of HLA class I and II alleles in COPD patients and healthy controls in a LA population with admixed ancestry. METHODS COPD patients (n=214) and age-matched controls (n=193) were genotyped using the Illumina Infinium Global Screening Array. The classic HLA alleles were imputed using HLA Genotype Imputation with Attribute Bagging (HIBAG) and the Hispanic reference panel. Finally, the distribution of HLA-DRB1 alleles was reexamined in 510 randomly recruited unrelated volunteers. RESULTS CODP patients showed a higher HLA-DRB1*01:02 allele frequency (6.54%) than healthy controls (3.27%, p=0.04, OR=2.07). HLA-DRB1*01:02 was also significantly associated with FEV1 (p=0.04) and oxygen saturation (p=0.02), and the FEV1/FVC ratio was higher in HLA-DRB1*15:01-positive patients (p=9×10-3). CONCLUSION We report an association among HLA-DRB1 alleles, COPD risk and pulmonary function parameters for the first time in Latin Americans. Since HLA-DRB1 genetic variability relates to the individual autoimmune response, these results support a role of autoimmunity in the pathogenesis of COPD.
Collapse
Affiliation(s)
- Roberto Díaz-Peña
- Laboratory of Cellular and Molecular Pathology, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile; Liquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain
| | - Rafael S Silva
- Unidad Respiratorio, Centro de Diagnóstico Terapéutico, Hospital Regional de Talca, Talca, Chile
| | - H Dean Hosgood
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Sergio Jaime
- Unidad Respiratorio, Centro de Diagnóstico Terapéutico, Hospital Regional de Talca, Talca, Chile
| | - Marc Miravitlles
- Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut de Recerca (VHIR), Barcelona, CIBER Enfermedades Respiratorias (CIBERES), Spain
| | - Jordi Olloquequi
- Laboratory of Cellular and Molecular Pathology, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile.
| |
Collapse
|
23
|
Barriales-Villa R, Ochoa JP, Larrañaga-Moreira JM, Salazar-Mendiguchía J, Díez-López C, Restrepo-Córdoba MA, Álvarez-Rubio J, Robles-Mezcua A, Olmo-Conesa MC, Nicolás-Rocamora E, Sanz J, Villacorta E, Gallego-Delgado M, Yotti R, Espinosa MÁ, Manovel A, Rincón-Díaz LM, Jiménez-Jaimez J, Bermúdez-Jiménez FJ, Basurte-Elorz MT, Climent-Payá V, García-Álvarez MI, Rodríguez-Palomares JF, Limeres-Freire J, Pérez-Guerrero A, Cantero-Pérez EM, Peña-Peña ML, Palomino-Doza J, Crespo-Leiro MG, García-Pinilla JM, Zorio E, Ripoll-Vera T, García-Pavía P, Ortiz-Genga M, Monserrat L. Risk predictors in a Spanish cohort with cardiac laminopathies. The REDLAMINA registry. ACTA ACUST UNITED AC 2020; 74:216-224. [PMID: 32616434 DOI: 10.1016/j.rec.2020.03.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2019] [Accepted: 03/03/2020] [Indexed: 01/27/2023]
Abstract
INTRODUCTION AND OBJECTIVES According to sudden cardiac death guidelines, an implantable cardioverter-defibrillator (ICD) should be considered in patients with LMNA-related dilated cardiomyopathy (DCM) and ≥ 2 risk factors: male sex, left ventricular ejection fraction (LVEF) <45%, nonsustained ventricular tachycardia (NSVT), and nonmissense genetic variants. In this study we aimed to describe the clinical characteristics of carriers of LMNA genetic variants among individuals from a Spanish cardiac-laminopathies cohort (REDLAMINA registry) and to assess previously reported risk criteria. METHODS The relationship between risk factors and cardiovascular events was evaluated in a cohort of 140 carriers (age ≥ 16 years) of pathogenic LMNA variants (54 probands, 86 relatives). We considered: a) major arrhythmic events (MAE) if there was appropriate ICD discharge or sudden cardiac death; b) heart failure death if there was heart transplant or death due to heart failure. RESULTS We identified 11 novel and 21 previously reported LMNA-related DCM variants. LVEF <45% (P=.001) and NSVT (P <.001) were related to MAE, but not sex or type of genetic variant. The only factor independently related to heart failure death was LVEF <45% (P <.001). CONCLUSIONS In the REDLAMINA registry cohort, the only predictors independently associated with MAE were NSVT and LVEF <45%. Therefore, female carriers of missense variants with either NSVT or LVEF <45% should not be considered a low-risk group. It is important to individualize risk stratification in carriers of LMNA missense variants, because not all have the same prognosis.
Collapse
Affiliation(s)
- Roberto Barriales-Villa
- Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña, A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
| | - Juan P Ochoa
- Departamento de Cardiología, Health in Code, A Coruña, Spain
| | - José M Larrañaga-Moreira
- Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña, A Coruña, Spain
| | - Joel Salazar-Mendiguchía
- Departamento de Cardiología, Health in Code, A Coruña, Spain; Unidad de Genética Clínica y Biología Molecular, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departamento de Genética, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
| | - Carles Díez-López
- Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
| | - María Alejandra Restrepo-Córdoba
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Insuficiencia Cardiaca y Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain; Red Europea de Referencia para enfermedades del corazón raras, de baja prevalencia y complejas (ERN GUARD-Heart), Spain
| | - Jorge Álvarez-Rubio
- Instituto de Investigación Sanitaria de las Islas Baleares (iDisBA), Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Balearic Islands, Spain
| | - Ainhoa Robles-Mezcua
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Insuficiencia Cardiaca y Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain
| | - María C Olmo-Conesa
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Red Europea de Referencia para enfermedades del corazón raras, de baja prevalencia y complejas (ERN GUARD-Heart), Spain; Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
| | - Elisa Nicolás-Rocamora
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Red Europea de Referencia para enfermedades del corazón raras, de baja prevalencia y complejas (ERN GUARD-Heart), Spain; Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
| | - Jorge Sanz
- Unidad de Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe), Instituto de Investigación Sanitaria La Fe, Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Eduardo Villacorta
- Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - María Gallego-Delgado
- Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain
| | - Raquel Yotti
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - María Ángeles Espinosa
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
| | - Ana Manovel
- Unidad de Hemodinámica y Ecocardiografía, Servicio de Cardiología, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain
| | - Luis M Rincón-Díaz
- Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - Juan Jiménez-Jaimez
- Servicio de Cardiología, Instituto de Investigación Biosanitaria de Granada (Ibs.Granada), Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - Francisco J Bermúdez-Jiménez
- Servicio de Cardiología, Instituto de Investigación Biosanitaria de Granada (Ibs.Granada), Hospital Universitario Virgen de las Nieves, Granada, Spain
| | | | - Vicente Climent-Payá
- Servicio de Cardiología, Hospital Universitario General de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain
| | - María I García-Álvarez
- Servicio de Cardiología, Hospital Universitario General de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain
| | - José Fernando Rodríguez-Palomares
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Javier Limeres-Freire
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Ainhoa Pérez-Guerrero
- Servicio de Cardiología, Hospital Universitario Miguel Servet de Zaragoza, Zaragoza, Spain
| | - Eva M Cantero-Pérez
- Unidad de Cardiopatías Familiares y Unidad de Imagen, Servicio de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - María L Peña-Peña
- Unidad de Cardiopatías Familiares y Unidad de Imagen, Servicio de Cardiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Julián Palomino-Doza
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - María G Crespo-Leiro
- Unidad de Cardiopatías Familiares, Servicio de Cardiología, Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña, A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - José M García-Pinilla
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Insuficiencia Cardiaca y Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain
| | - Esther Zorio
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe), Instituto de Investigación Sanitaria La Fe, Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Tomás Ripoll-Vera
- Instituto de Investigación Sanitaria de las Islas Baleares (iDisBA), Unidad de Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Son Llàtzer, Palma de Mallorca, Balearic Islands, Spain
| | - Pablo García-Pavía
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Unidad de Insuficiencia Cardiaca y Cardiopatías Familiares, Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain; Red Europea de Referencia para enfermedades del corazón raras, de baja prevalencia y complejas (ERN GUARD-Heart), Spain; Facultad de Medicina, Universidad Francisco de Vitoria (UFV), Pozuelo de Alarcón, Madrid, Spain
| | | | - Lorenzo Monserrat
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Departamento de Cardiología, Health in Code, A Coruña, Spain
| |
Collapse
|
24
|
Dal-Ré R. Analysis of biomedical Spanish articles retracted between 1970 and 2018. Med Clin (Barc) 2020; 154:125-130. [PMID: 31239080 DOI: 10.1016/j.medcli.2019.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Revised: 04/08/2019] [Accepted: 04/11/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND AND OBJECTIVE To analyse articles retracted due to irregularities by authors helps to determine the state of scientific integrity of a discipline or country. The Retraction Watch (RW) database is the largest worldwide database on retracted articles. The objective was to determine the reasons for and features of retracted biomedical articles by Spanish authors. MATERIAL AND METHODS A search was conducted in the RW database of 7 types of scientific articles from 9 biomedicine disciplines -biology, genetics, medicine, microbiology, neurosciences, nutrition, dentistry, public health and toxicology-, with at least one author working in a Spanish centre, and published between 1970 and 2018. The features of the articles and the reasons for their retraction were recorded. RESULTS Of the 18,621 retracted articles, 217 (1%) were by Spanish authors; 155 (74%) were on biomedicine and the types of articles of interest. In most cases, there were several reasons for retracting an article. Research misconduct (fabrication, falsification, plagiarism) and duplication were involved in 25% and 35% of the cases, respectively. Twenty-two percent of the articles were retracted due to errors by the authors or the journals. A dentist retracted 18 articles -all from the same journal and in the same year, 2018-, which accounts for 12% of all retracted biomedicine articles. CONCLUSION The number of retracted biomedicine articles by Spanish authors is low. Research misconduct was a frequent reason, with a similar percentage of articles retracted due to honest errors.
Collapse
Affiliation(s)
- Rafael Dal-Ré
- Unidad de Epidemiología, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Hospital Universitario, Universidad Autónoma de Madrid, Madrid, España.
| |
Collapse
|
25
|
Oliveira SC, Neves JS, Pérez A, Carvalho D. Maturity-onset diabetes of the young: From a molecular basis perspective toward the clinical phenotype and proper management. ACTA ACUST UNITED AC 2019; 67:137-147. [PMID: 31718996 DOI: 10.1016/j.endinu.2019.07.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Revised: 07/04/2019] [Accepted: 07/09/2019] [Indexed: 12/28/2022]
Abstract
Maturity-onset diabetes of the young (MODY) comprises a heterogeneous group of monogenic disorders characterized by primary defect in pancreatic β-cell function, early onset and autosomal dominant inheritance, accounting for about 1-5% of all diabetes diagnoses. Mutations in 14 genes are responsible for the majority of all MODY cases described so far. The clinical phenotype relies on genetic defects, with important implications in the optimal treatment and prognosis definition. MODY's early diagnosis remains a challenge, since this group of inherited disorders comprises a large clinical spectrum and it usually overlaps with other types of diabetes, requiring a high index of suspicion even if the definitive statement demands a molecular genetic study. Recent advances on the genetic determinants and pathophysiology of MODY have allowed a better understanding of its underlying molecular mechanisms, providing a proper genetic counseling and early diagnosis. These new management insights will make possible to set up new therapeutic strategies, with drugs able to prevent, correct or at least delay the decline of pancreatic β-cell function, thus affording for a more personalized treatment and, ultimately, for a better patient care.
Collapse
Affiliation(s)
- Sofia Castro Oliveira
- Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal; Faculty of Medicine of the Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
| | - João Sérgio Neves
- Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal; Faculty of Medicine of the Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
| | - Antonio Pérez
- Department of Endocrinology and Nutrition, Hospital Santa Creu i Sant Pau, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain; CIBER de Diabetes y Enfermidades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - Davide Carvalho
- Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal; Faculty of Medicine of the Universidade do Porto, Porto, Portugal; Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
| |
Collapse
|
26
|
Gómez Alcaraz J, Bustamante J, Corral E, Casado Florez MI, Vivas D, Cañadas-Godoy V, González Del Castillo J, González Armengol JJ, López-Farré A, Martín Sánchez FJ. Genetic mutations in young patients admitted to an emergency department for syncope during sport practice. Med Clin (Barc) 2018; 151:270-4. [PMID: 29705154 DOI: 10.1016/j.medcli.2018.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 03/13/2018] [Accepted: 03/15/2018] [Indexed: 11/22/2022]
Abstract
BACKGROUND AND OBJECTIVES To study the frequency of genetic mutations related to genetic heart disease among young patients admitted for syncope during sport practice. PATIENTS AND METHODS A case series study that included patients≤45 years admitted for syncope during sport practice during 2010-2011. We collected demographic and clinical variables, genetic tests mutations and final clinical diagnosis. RESULTS A genetic test was performed in 46 (76.7%) of 60 patients evaluated. The genetic test was positive in 12 (26%; 95% CI 15.6-40.3) patients; 10 (21.7%) had PKP2 mutation related to arrhythmogenic right ventricular dysplasia mutation, one (2.2%) KCNQ1 mutation and one (2.2%) SCN5A mutation related to channelopathies. The genetic test was positive in 11 (35.5%) cases of undetermined syncope and one (50%) case of cardiac syncope, being negative in all cases with neuromediated syncopes (P=.037). CONCLUSIONS Gene mutations are common in young patients suffering from syncope during sports, especially in those with cardiac or undetermined aetiology.
Collapse
|
27
|
Felix F, Ribeiro MG, Tomita S, Zalis MG. Frequency of GJB2 mutations in patients with nonsyndromic hearing loss from an ethnically characterized Brazilian population. Braz J Otorhinolaryngol 2018; 85:92-98. [PMID: 29773520 PMCID: PMC9442831 DOI: 10.1016/j.bjorl.2017.10.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 09/25/2017] [Accepted: 10/27/2017] [Indexed: 11/24/2022] Open
Abstract
Introduction In different parts of the world, mutations in the GJB2 gene are associated with nonsyndromic hearing loss, and the homozygous 35delG mutation (p.Gly12Valfs*2) is a major cause of hereditary hearing loss. However, the 35delG mutation is not equally prevalent across ethnicities, making it important to study other mutations, especially in multiethnic countries such as Brazil. Objective This study aimed to identify different mutations in the GJB2 gene in patients with severe to profound nonsyndromic sensorineural hearing loss of putative genetic origin, and who were negative or heterozygote for the 35delG mutation. Methods Observational study that analyzed 100 ethnically characterized Brazilian patients with nonsyndromic severe to profound sensorineural hearing loss, who were negative or heterozygote for the 35delG mutation. GJB2 mutations were detected by DNA-based sequencing in this population. Participants’ ethnicities were identified as Latin European, Non-Latin European, Jewish, Native, Turkish, Afro-American, Asian and Others. Results Sixteen participants were heterozygote for the 35delG mutation; 14 participants, including three 35delG heterozygote's, had nine different alterations in the GJB2 gene. One variant, p.Ser199Glnfs*9, detected in two participants, was previously unreported. Three variants were pathogenic (p.Trp172*, p.Val167Met, and p.Arg75Trp), two were non-pathogenic (p.Val27Ile and p.Ile196Thr), and three variants were indeterminate (p.Met34Thr, p.Arg127Leu, and p.Lys168Arg). Three cases of compound heterozygosity were detected: p.[(Gly12Valfs*2)];[(Trp172*)], p.[(Gly12Valfs*2)](;)[(Met34Thr)], and p.[(Gly12Valfs*2)(;)[(Ser199Glnfs*9)]). Conclusion This study detected previously unclassified variants and one case of previously unreported compound heterozygosity.
Collapse
Affiliation(s)
- Felippe Felix
- Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho (HUCFF), Rio de Janeiro, RJ, Brazil.
| | - Marcia Gonçalves Ribeiro
- Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho (HUCFF), Rio de Janeiro, RJ, Brazil
| | - Shiro Tomita
- Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho (HUCFF), Rio de Janeiro, RJ, Brazil
| | - Mariano Gustavo Zalis
- Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho (HUCFF), Rio de Janeiro, RJ, Brazil
| |
Collapse
|
28
|
Abstract
Ischemic heart disease continues to cause high morbidity and mortality. Its prevalence is expected to increase due to population aging, and its prevention is a major goal of health policies. The risk of developing ischemic heart disease is related to a complex interplay between genetic, environmental, and lifestyle factors. In the last decade, considerable progress has been made in knowledge of the genetic architecture of this disease. This narrative review provides an overview of current knowledge of the genetics of ischemic heart disease and of its translation to clinical practice: identification of new therapeutic targets, assessment of the causal relationship between biomarkers and disease, improved risk prediction, and identification of responders and nonresponders to specific drugs (pharmacogenomics).
Collapse
Affiliation(s)
- Roberto Elosua
- Grupo de Epidemiología y Genética Cardiovascular, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Barcelona, Spain.
| | - Sergi Sayols-Baixeras
- Grupo de Epidemiología y Genética Cardiovascular, Instituto Hospital del Mar de Investigaciones Médicas (IMIM), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Barcelona, Spain; Departamento de Ciencias de la Salud y de la Vida, Universidad Pompeu Fabra, Barcelona, Spain
| |
Collapse
|
29
|
Abstract
The observation that "one size does not fit all" for the prevention and treatment of cardiovascular disease, among other diseases, has driven the concept of precision medicine. The goal of precision medicine is to provide the best-targeted interventions tailored to an individual's genome. The human genome is composed of billions of sequence arrangements containing a code that controls how genes are expressed. This code depends on other nonstatic regulators that surround the DNA and constitute the epigenome. Moreover, environmental factors also play an important role in this complex regulation. This review provides a general perspective on the basic concepts of molecular biology related to genetics and epigenetics and a glossary of key terms. Several examples are given of polymorphisms and genetic risk scores related to cardiovascular risk. Likewise, an overview is presented of the main epigenetic regulators, including DNA methylation, methylcytosine-phosphate-guanine-binding proteins, histone modifications, other histone regulations, micro-RNA effects, and additional emerging regulators. One of the greatest challenges is to understand how environmental factors (diet, physical activity, smoking, etc.) could alter the epigenome, resulting in healthy or unhealthy cardiovascular phenotypes. We discuss some gene-environment interactions and provide a methodological overview.
Collapse
Affiliation(s)
- Dolores Corella
- Departamento de Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de Valencia, Valencia, Spain; CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain.
| | - Jose M Ordovas
- Departamento de Epidemiología Cardiovascular y Genética de Poblaciones, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Instituto Madrileño de Estudios Avanzados (IMDEA) Alimentación, Madrid, Spain; Nutrition and Genomics Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts, United States
| |
Collapse
|
30
|
Santana Del Pino A, Medina-Rodríguez N, Hernández-García M, Nóvoa-Mogollón FJ, Wägner AM. Is HLA the cause of the high incidence of type 1 diabetes in the Canary Islands? Results from the Type 1 Diabetes Genetics Consortium (T1DGC). Endocrinol Diabetes Nutr 2017; 64:146-151. [PMID: 28440753 DOI: 10.1016/j.endinu.2016.12.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 12/03/2016] [Accepted: 12/06/2016] [Indexed: 01/25/2023]
Abstract
INTRODUCTION Incidence of childhood-onset type 1 diabetes mellitus in the Canary Islands is the highest reported so far in Spain, and among the highest worldwide. The HLA region accounts for approximately half the genetic risk of type 1 diabetes. Our aim was to assess distribution of high-risk and protective HLA haplotypes in the Canarian families included in the T1DGC, as compared to the rest of Spain. METHODS The T1DGC study, an international project to study the genetics and pathogenesis of type 1 diabetes, enrolled more than 3000 families with type 1 diabetes worldwide. Spain provided 149 of these families, of whom 42 were from Tenerife and Gran Canaria. HLA was genotyped centrally using a PCR-based, sequence-specific oligonucleotide probe system. Haplotypes were reconstructed using the deterministic algorithm alleHap in the R programming environment. Based on prior T1DGC results in Caucasian population, haplotypes DRB1*0405-DQA1*0301-DQB1*0302, DRB1*0401-DQA1*0301-DQB1*0302, DRB1*0301-DQA1*0501-DQB1*0201, DRB1*0402-DQA1*0301-DQB1*0302 and DRB1*0404-DQA1*0301-DQB1*0302 were considered high-risk. DRB1*0701-DQA1*0201-DQB1*0303, DRB1*1401-DQA1*0101-DQB1*0503, DRB1*1501-DQA1*0102-DQB1*0602, DRB1*1101-DQA1*0501-DQB1*0301, DRB1*1104-DQA1*0501-DQB1*0301, DRB1*1303-DQA1*0501-DQB1*0301, DRB1*1301-DQA1*0103-DQB1*0603 and DRB1*0403-DQA1*0301-DQB1*0302 were considered protective. The distribution of protective, high-risk, and other haplotypes in the (first two) affected siblings and unaffected parents from Canarian and non-Canarian Spanish families was compared (Chi-square test). RESULTS No significant differences were found between the regions in distribution of the HLA haplotypes in the affected siblings or in the non-affected parents. CONCLUSIONS The high incidence of childhood-onset type 1 diabetes in the Canarian population does not appear to be explained by a greater prevalence of high-risk class II HLA haplotypes in families with the disease. However, sample size limits the differences that can be detected in this study.
Collapse
Affiliation(s)
- Angelo Santana Del Pino
- Mathematics and Statistics Dept, Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain
| | - Nathan Medina-Rodríguez
- Instituto Universitario de Microelectrónica Aplicada, ULPGC, Las Palmas de Gran Canaria, Spain
| | - Marta Hernández-García
- Endocrinology Dept, Hospital Universitari Arnau de Vilanova, Lleida, Spain; Institut de Recerca Biomèdica de Lleida (IRB Lleida), Lleida, Spain
| | - Francisco J Nóvoa-Mogollón
- Endocrinology Dept, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain; Instituto Universitario de Investigaciones Biomédicas y Sanitarias, ULPGC, Las Palmas de Gran Canaria, Spain
| | - Ana M Wägner
- Endocrinology Dept, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain; Instituto Universitario de Investigaciones Biomédicas y Sanitarias, ULPGC, Las Palmas de Gran Canaria, Spain.
| |
Collapse
|
31
|
Núñez-Batalla F, Jáudenes-Casaubón C, Sequí-Canet JM, Vivanco-Allende A, Zubicaray-Ugarteche J, Cabanillas-Farpón R. Aetiological diagnosis of child deafness: CODEPEH recommendations. Acta Otorrinolaringol Esp 2017; 68:43-55. [PMID: 27644946 DOI: 10.1016/j.otorri.2016.05.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Accepted: 05/19/2016] [Indexed: 12/18/2022]
Abstract
Important progress in the fields of molecular genetics (principally) and diagnostic imaging, together with the lack of a consensus protocol for guiding the diagnostic process after confirming deafness by neonatal screening, have led to this new work document drafted by the Spanish Commission for the Early Detection of Child Deafness (Spanish acronym: CODEPEH). This 2015 Recommendations Document, which is based on the most recent scientific evidence, provides guidance to professionals to support them in making decisions regarding aetiological diagnosis. Such diagnosis should be performed without delay and without impeding early intervention. Early identification of the causes of deafness offers many advantages: it prevents unnecessary trouble for the families, reduces health system expenses caused by performing different tests, and provides prognostic information that may guide therapeutic actions.
Collapse
|
32
|
Reuter CP, Burgos MS, Bernhard JC, Tornquist D, Klinger EI, Borges TS, Renner JDP, de Moura Valim AR, de Mello ED. Association between overweight and obesity in schoolchildren with rs9939609 polymorphism (FTO) and family history for obesity. J Pediatr (Rio J) 2016; 92:493-8. [PMID: 27154418 DOI: 10.1016/j.jped.2015.11.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Revised: 11/16/2015] [Accepted: 11/25/2015] [Indexed: 01/19/2023] Open
Abstract
OBJECTIVE To determine the association between overweight/obesity in schoolchildren with FTO rs9939609 polymorphism (fatmass and obesity associated) and family history of obesity. METHODS Cross-sectional study comprising a sample of 406 children aged 7-17 years in a city in southern Brazil. Overweight/obesity in schoolchildren was assessed by body mass index (BMI), and family history of obesity was self-reported by parents. Polymorphism genotyping was performed by real time PCR (polymerase chain reaction). The association between the nutritional status of schoolchildren with the presence of family obesity, stratified by polymorphism genotypes (AA [at-risk for obesity], AT, and TT), was assessed by prevalence ratio values (PR) through Poisson regression. RESULTS Among schoolchildren with the AA genotype, 57.4% had overweight/obesity; the percentage was lower for the AT and TT genotypes (33.1% and 28.9%, respectively). Overweight/obesity in schoolchildren was associated with a family history of obesity, especially among children with the AA genotype. The prevalence was higher among those with an obese mother (PR: 1.28; p<0.001), obese maternal or paternal grandmother (PR: 1.22; p=0.047), and obese paternal grandfather (PR: 1.32; p<0.001). CONCLUSIONS There is an association between the AA genotype of rs9939609 polymorphism and BMI among schoolchildren. The association between overweight/obesity in schoolchildren with a family history of obesity was found mainly among students with the AA genotype.
Collapse
Affiliation(s)
- Cézane Priscila Reuter
- Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Universidade de Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil.
| | | | | | - Debora Tornquist
- Universidade de Santa Cruz do Sul, Santa Cruz do Sul, RS, Brazil
| | | | | | | | | | | |
Collapse
|
33
|
Lario A, de Miguel C, Ojeda E, Gil S, Coll MJ, Alfonso P. [New mutation in a young woman diagnosed with Niemann-Pick disease type C]. Med Clin (Barc) 2016; 146:494-6. [PMID: 27016452 DOI: 10.1016/j.medcli.2016.01.031] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 01/23/2016] [Accepted: 01/28/2016] [Indexed: 10/22/2022]
Abstract
BACKGROUND AND OBJETIVE To describe a new molecular variant of Niemann-Pick disease type C (NPC) in a 27 year-old patient with splenomegaly and abolition of osteotendinous reflexes. MATERIAL AND METHODS NPC1 is the main gene with described mutation in NPC disease. Here we report a case with a new mutation, p.N916S, not described before in a patient diagnosed with NPC. RESULTS p.N916S was described as a cause of NPC disease by predictive programmes Mutation Master, PolyPhen2 and SIFT. CONCLUSIONS p.N916S is a new mutation detected as a cause of NPC disease in a patient without severe neurological symptoms.
Collapse
Affiliation(s)
- Ana Lario
- Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España.
| | - Carlos de Miguel
- Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España
| | - Emilio Ojeda
- Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España
| | - Santiago Gil
- Servicio de Hematología y Hemoterapia, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España
| | - María J Coll
- Centro de Diagnóstico Biomédico, Hospital Clínic, Barcelona, España
| | - Pilar Alfonso
- Departamento de Bioquímica y Biología Celular y Molecular, Universidad de Zaragoza, Zaragoza, España
| |
Collapse
|
34
|
Ochoa-Gómez L, López-Pisón J, Fuertes-Rodrigo C, Fernando-Martínez R, Samper-Villagrasa P, Monge-Galindo L, Peña-Segura JL, García-Jiménez MC. Descriptive study of symptomatic epilepsy by age of onset in patients with a 3-year follow-up at the Neuropaediatric Department of a reference centre. Neurologia 2016; 32:455-462. [PMID: 27091679 DOI: 10.1016/j.nrl.2016.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2015] [Revised: 02/01/2016] [Accepted: 02/25/2016] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE We conducted a descriptive study of symptomatic epilepsy by age at onset in a cohort of patients who were followed up at a neuropaediatric department of a reference hospital over a 3-year period PATIENTS AND METHODS: We included all children with epilepsy who were followed up from January 1, 2008 to December 31, 2010 RESULTS: Of the 4595 children seen during the study period, 605 (13.17%) were diagnosed with epilepsy; 277 (45.79%) of these had symptomatic epilepsy. Symptomatic epilepsy accounted for 67.72% and 61.39% of all epilepsies starting before one year of age, or between the ages of one and 3, respectively. The aetiologies of symptomatic epilepsy in our sample were: prenatal encephalopathies (24.46% of all epileptic patients), perinatal encephalopathies (9.26%), post-natal encephalopathies (3.14%), metabolic and degenerative encephalopathies (1.98%), mesial temporal sclerosis (1.32%), neurocutaneous syndromes (2.64%), vascular malformations (0.17%), cavernomas (0.17%), and intracranial tumours (2.48%). In some aetiologies, seizures begin before the age of one; these include Down syndrome, genetic lissencephaly, congenital cytomegalovirus infection, hypoxic-ischaemic encephalopathy, metabolic encephalopathies, and tuberous sclerosis. CONCLUSIONS The lack of a universally accepted classification of epileptic syndromes makes it difficult to compare series from different studies. We suggest that all epilepsies are symptomatic because they have a cause, whether genetic or acquired. The age of onset may point to specific aetiologies. Classifying epilepsy by aetiology might be a useful approach. We could establish 2 groups: a large group including epileptic syndromes with known aetiologies or associated with genetic syndromes which are very likely to cause epilepsy, and another group including epileptic syndromes with no known cause. Thanks to the advances in neuroimaging and genetics, the latter group is expected to become increasingly smaller.
Collapse
Affiliation(s)
- L Ochoa-Gómez
- Unidad de Neuropediatría, Hospital Miguel Servet, Zaragoza, España
| | - J López-Pisón
- Unidad de Neuropediatría, Hospital Miguel Servet, Zaragoza, España.
| | | | | | | | - L Monge-Galindo
- Unidad de Neuropediatría, Hospital Miguel Servet, Zaragoza, España
| | - J L Peña-Segura
- Unidad de Neuropediatría, Hospital Miguel Servet, Zaragoza, España
| | | |
Collapse
|
35
|
Cruz-González F, Cabrillo Estévez L, Cañete Campos C, Sánchez-Jara Sánchez A, Juan Marcos L, González-Sarmiento R. The presence of CFH, HTRA1, ARMS2, VEGF-A and VEGF-R and the appearance of age-related macular degeneration sub-types. Arch Soc Esp Oftalmol 2016; 91:177-83. [PMID: 26850328 DOI: 10.1016/j.oftal.2015.12.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2015] [Revised: 12/23/2015] [Accepted: 12/25/2015] [Indexed: 06/05/2023]
Abstract
OBJECTIVE To demonstrate the genetic influence in the onset of the different age-related macular disease (AMD) subtypes by analysing the genotype distribution of CFH, ARMS2, HTRA1, VEGF-A and VEGF-R polymorphisms in patients with neovascular and atrophic AMD. MATERIALS AND METHODS The study was conducted on 101 consecutive patients with AMD diagnosis (74 exudative, 27 atrophic) following Wisconsin international classification criteria. The CFH rs1410996, ARMS2 rs10940923, VEGF-A rs833061, rs699947, and VEGF-R rs2071559 polymorphisms were analysed using real time PCR with taqman probes, and HTRA1 rs112000638 using restriction endonucleases digestion. A study was made of the genotype distribution of the different polymorphisms in our group of patients with neovascular AMD and those with the atrophic type, and a comparison was made of the results for each one of the genes studied. RESULTS No statistically significant differences (P>.05) were found in the genotype distribution of the different polymorphisms between patients with neovascular AMD and patients with atrophic AMD in our population, although the "risk" genotypes tended to appear more frequently in patients with neovascular AMD, despite the lack of statistical significance. CONCLUSIONS Allelic variants of CFH, ARMS2, HTRA1, VEGF-A or VEGF-R genes are not associated with the different AMD subtypes. This suggests that, although the polymorphisms seem to be associated with the disease susceptibility, they are not involved in the onset of the different clinical variants of AMD. Further studies in different populations, and with a larger cohort of patients, are needed to confirm these results.
Collapse
Affiliation(s)
- F Cruz-González
- Servicio de Oftalmología, Hospital Universitario de Salamanca, Salamanca, España.
| | - L Cabrillo Estévez
- Servicio de Oftalmología, Instituto Salmantino de Oftalmología, Salamanca, España
| | - C Cañete Campos
- Servicio de Oftalmología, Hospital Universitario de Salamanca, Salamanca, España
| | | | - L Juan Marcos
- Servicio de Oftalmología, Hospital Universitario de Salamanca, Salamanca, España
| | - R González-Sarmiento
- Departamento de Medicina Molecular, Facultad de Medicina, Universidad de Salamanca, Salamanca, España
| |
Collapse
|
36
|
Mauro-Martin IS, De la Calle-de la Rosa L, Sanz-Rojo S, Garicano-Vilar E, Ciudad-Cabañas MJ, Collado-Yurrita L. [Not Available]. NUTR HOSP 2016; 33:23. [PMID: 27019250 DOI: 10.20960/nh.v33i1.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 02/17/2016] [Indexed: 06/05/2023] Open
|
37
|
Abstract
Multiple sclerosis occurs in genetically susceptible individuals, in whom an unknown environmental factor triggers an immune response, giving rise to a chronic and disabling autoimmune disease. Currently, significant progress is being made in our knowledge of the frequency and distribution of multiple sclerosis and its risk factors, genetics, pathology, pathogenesis, diagnostic and prognostic markers, and treatment. This has radically changed patients' and clinicians' expectations of multiple sclerosis and has raised hope that there will soon be a way to control the disease.
Collapse
Affiliation(s)
- Óscar Fernández
- Unidad de Gestión Clínica de Neurociencias, Servicio de Neurología, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, España; Instituto de Investigación en Biomedicina de Málaga (IBIMA), Universidad de Málaga, Málaga, España.
| |
Collapse
|
38
|
Abstract
OBJECTIVE Distal renal tubular acidosis (dRTA) is characterized by metabolic acidosis due to impaired renal acid excretion. The aim of this study was to demonstrate the genetic diagnosis of four children with dRTA through use of whole-exome sequencing. METHODS Two unrelated families were selected; a total of four children with dRTA and their parents, in order to perform whole-exome sequencing. Hearing was preserved in both children from the first family, but not in the second, wherein a twin pair had severe deafness. Whole-exome sequencing was performed in two pooled samples and findings were confirmed with Sanger sequencing method. RESULTS Two mutations were identified in the ATP6V0A4 and ATP6V1B1 genes. In the first family, a novel mutation in the exon 13 of the ATP6V0A4 gene with a single nucleotide change GAC → TAC (c.1232G>T) was found, which caused a substitution of aspartic acid to tyrosine in position 411. In the second family, a homozygous recurrent mutation with one base-pair insertion (c.1149_1155insC) in exon 12 of the ATP6V1B1 gene was detected. CONCLUSION These results confirm the value of whole-exome sequencing for the study of rare and complex genetic nephropathies, allowing the identification of novel and recurrent mutations. Furthermore, for the first time the application of this molecular method in renal tubular diseases has been clearly demonstrated.
Collapse
Affiliation(s)
- Paula Cristina Barros Pereira
- Instituto Nacional de Ciência e Tecnologia - Medicina Molecular (INCT-MM), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Flávia Medeiros Melo
- Instituto Nacional de Ciência e Tecnologia - Medicina Molecular (INCT-MM), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Luiz Armando Cunha De Marco
- Instituto Nacional de Ciência e Tecnologia - Medicina Molecular (INCT-MM), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Department of Surgery, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Eduardo Araújo Oliveira
- Instituto Nacional de Ciência e Tecnologia - Medicina Molecular (INCT-MM), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Department of Pediatrics, Unit of Pediatric Nephrology, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Débora Marques Miranda
- Instituto Nacional de Ciência e Tecnologia - Medicina Molecular (INCT-MM), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Department of Pediatrics, Unit of Pediatric Nephrology, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil
| | - Ana Cristina Simões e Silva
- Instituto Nacional de Ciência e Tecnologia - Medicina Molecular (INCT-MM), Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil; Department of Pediatrics, Unit of Pediatric Nephrology, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
| |
Collapse
|
39
|
Ripoll-Vera T, Gámez JM, Govea N, Gómez Y, Núñez J, Socías L, Escandell Á, Rosell J. Clinical and Prognostic Profiles of Cardiomyopathies Caused by Mutations in the Troponin T Gene. ACTA ACUST UNITED AC 2016; 69:149-58. [PMID: 26507537 DOI: 10.1016/j.rec.2015.06.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2015] [Accepted: 06/29/2015] [Indexed: 11/20/2022]
Abstract
INTRODUCTION AND AIMS Mutations in the troponin T gene (TTNT2) have been associated in small studies with the development of hypertrophic cardiomyopathy characterized by a high risk of sudden death and mild hypertrophy. We describe the clinical course of patients carrying mutations in this gene. METHODS We analyzed the clinical characteristics and prognosis of patients with mutations in the TNNT2 gene who were seen in an inherited cardiac disease unit. RESULTS Of 180 families with genetically studied cardiomyopathies, 21 families (11.7%) were identified as having mutations in TNNT2: 10 families had Arg92Gln, 5 had Arg286His, 3 had Arg278Cys, 1 had Arg92Trp, 1 had Arg94His, and 1 had Ile221Thr. Thirty-three additional genetic carriers were identified through family assessment. The study included 54 genetic carriers: 56% were male, and the mean average age was 41 ± 17 years. There were 33 cases of hypertrophic cardiomyopathy, 9 of dilated cardiomyopathy, and 1 of noncompaction cardiomyopathy, and maximal myocardial thickness was 18.5 ± 6mm. Ventricular dysfunction was present in 30% of individuals and a history of sudden death in 62%. During follow-up, 4 patients died and 14 (33%) received a defibrillator (8 probands, 6 relatives). Mean survival was 54 years. Carriers of Arg92Gln had early disease development, high penetrance, a high risk of sudden death, a high rate of defibrillator implantation, and a high frequency of mixed phenotype. CONCLUSIONS Mutations in the TNNT2 gene were more common in this series than in previous studies. The clinical and prognostic profiles depended on the mutation present. Carriers of the Arg92Gln mutation developed hypertrophic or dilated cardiomyopathy and had a significantly worse prognosis than those with other mutations in TNNT2 or other sarcomeric genes.
Collapse
|
40
|
Iranzo-Tatay C, Gimeno-Clemente N, Livianos-Aldana L, Rojo-Moreno L. [Genetic and environmental contributions to body mass index in a Spanish adolescent twin sample]. Med Clin (Barc) 2015; 145:153-9. [PMID: 25066500 DOI: 10.1016/j.medcli.2014.05.039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Revised: 05/17/2014] [Accepted: 05/22/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND AND OBJECTIVE Twin and family studies support large genetic influences on variability in body mass index (BMI), with heritability estimates ranging from 47% to over 90%. Our objective was to study the relative contributions of genetics and environment to BMI, evaluating sex differences, in an adolescent twin sample from Valencia, Spain. MATERIAL AND METHODS Five hundred eighty-four pairs of adolescent twins between 13 and 18 years of age completed the study (82 monozygotic [MZ] and 87 dizygotic [DZ] pairs of male twins, 118 MZ and 102 DZ pairs of female twins, and 195 opposite-sex pairs of DZ twins). To determine zygosity, teachers responded a questionnaire on physical similarity. They also measured the participant's height and weight. BMI was calculated and weight status was determined according to age. We used twin models to assess genetic and environmental (common and unique) factors affecting BMI. RESULTS There was a 7.1% frequency of overweight and 2.8% of obesity. The estimated heritability of BMI was 88.0% in boys and 72.1% in girls, with the remaining variance attributable to non-shared environment in boys (12.0%) and 8.8% in girls. It was only in girls that common environment had an effect on BMI. CONCLUSIONS Genetics appears to play an important role in explaining the variability in BMI in the adolescence, with slight variations between boys and girls. Common environmental factors exert their influence on BMI only in girls.
Collapse
Affiliation(s)
- Carmen Iranzo-Tatay
- Servicio de Psiquiatría, Hospital Universitario y Politécnico La Fe, Valencia, España.
| | - Natalia Gimeno-Clemente
- Grupo de investigación Psiquiátrica, Sección de Psiquiatría Infanto-Juvenil, Hospital Universitario La Fe, Valencia, España
| | - Lorenzo Livianos-Aldana
- Servicio de Psiquiatría, Hospital Universitario y Politécnico La Fe, Valencia, España; Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP); Departamento de Psiquiatría, Facultad de Medicina, Universidad de Valencia, Valencia, España
| | - Luis Rojo-Moreno
- Servicio de Psiquiatría, Hospital Universitario y Politécnico La Fe, Valencia, España; Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP); Departamento de Psiquiatría, Facultad de Medicina, Universidad de Valencia, Valencia, España
| |
Collapse
|
41
|
Rojo-Moreno L, Iranzo-Tatay C, Gimeno-Clemente N, Barberá-Fons MA, Rojo-Bofill LM, Livianos-Aldana L. Genetic and environmental influences on psychological traits and eating attitudes in a sample of Spanish schoolchildren. Rev Psiquiatr Salud Ment 2015; 10:134-142. [PMID: 26163975 DOI: 10.1016/j.rpsm.2015.05.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2014] [Revised: 05/21/2015] [Accepted: 05/28/2015] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The heritability of eating disorders has been estimated to range from 22% to over 62%.The aim of this study is to determine the relative influence of genetics and environment that contribute to the drive for thinness, body dissatisfaction, perfectionism, and ineffectiveness, by evaluating sex differences in a sample of adolescent twins from Valencia, Spain. MATERIAL AND METHODS Five hundred eighty-four pairs of adolescent twins between 13 and 18 years of age completed the study. To determine zygosity, teachers responded to a questionnaire on physical similarity. Psychological traits of eating disorders were assessed with four sub-scales of the Eating Disorder Inventory (EDI); drive for thinness, body dissatisfaction, perfectionism, and ineffectiveness. Twin models were used to assess genetic and environmental (common and unique) factors affecting these four psychological traits. RESULTS All four traits showed significant genetic contributions among girls, with heritability estimates of 37.7% for ineffectiveness, 42.8% for perfectionism, 56.9% for drive for thinness, and 65.5% for body dissatisfaction. Among boys, body dissatisfaction showed no additive genetic contributions, indicating significant shared and individual specific environment effects. The three other traits in boys showed significant additive genetic contributions, but were lower than in girls. CONCLUSIONS With the exception of body dissatisfaction in boys, psychological traits of eating disorders show heritability patterns that differ according to sex.
Collapse
Affiliation(s)
- Luis Rojo-Moreno
- Servicio de Psiquiatría, Hospital Universitario y Politécnico La Fe, Valencia, España; CIBERESP, España; Departamento de Psiquiatría, Facultad de Medicina, Universidad de Valencia, Valencia, España
| | - Carmen Iranzo-Tatay
- Servicio de Psiquiatría, Hospital Universitario y Politécnico La Fe, Valencia, España.
| | - Natalia Gimeno-Clemente
- Grupo de investigación Psiquiátrica, Sección de Psiquiatría Infanto-Juvenil, Hospital Universitario La Fe, Valencia, España
| | | | | | - Lorenzo Livianos-Aldana
- Servicio de Psiquiatría, Hospital Universitario y Politécnico La Fe, Valencia, España; CIBERESP, España; Departamento de Psiquiatría, Facultad de Medicina, Universidad de Valencia, Valencia, España
| |
Collapse
|
42
|
Ruiz del Río N, Abelairas Gómez JM, Alonso García de la Rosa FJ, Peralta Calvo JM, de las Heras Martín A. [Genetic analysis results of patients with a retinoblastoma refractory to systemic chemotherapy]. ACTA ACUST UNITED AC 2015; 90:414-20. [PMID: 25817468 DOI: 10.1016/j.oftal.2015.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 09/09/2014] [Accepted: 02/09/2015] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To analyze the genetic alterations identified in the RB1 gene in retinoblastoma patients who do not respond to systemic chemotherapy. METHODS A genetic analysis was performed on 115 patients with retinoblastoma, 40 of whom had received systemic chemotherapy, and 29 of them had bilateral disease. Descriptive and retrospective study. Non-responders were considered as patients who are finally enucleated. RESULTS Patients with deletion type mutations are those with less preservation of the eyeball (Pearson Chi-square, P=.055). Patients with an impaired nonsense-frameshift type are more likely to preserve the eyeball. Of the 3 patients who had undergone bilateral enucleation, 2 of them had deletions and one missense alteration. Survival analysis (Kaplan-Meier curve) shows that patients with deletion type mutations are more resistance to chemotherapy, are suffering higher rates of enucleation, and for a shorter period of time (log rank [Mantel-Cox] with a significance level of P=.053), which are also associated with increased rate of being bilateral. CONCLUSIONS Patients with a genotype show increased resistance to chemotherapy should be evaluated more closely and treated with various therapeutic weapons early. Patients that have deletions in the RB1 gene are at increased risk of chemoresistance. It is likely that other genetic alterations other than RB1 gene may be related to tumor aggressiveness and treatment resistance.
Collapse
Affiliation(s)
- N Ruiz del Río
- Servicio de Oftalmología, Hospital Manises, Valencia, España.
| | - J M Abelairas Gómez
- Servicio de Oftalmología Infantil, Hospital Universitario La Paz, Madrid, España
| | | | - J M Peralta Calvo
- Servicio de Oftalmología Infantil, Hospital Universitario La Paz, Madrid, España
| | | |
Collapse
|
43
|
Larcher F, Del Río M. Innovative therapeutic strategies for recessive dystrophic epidermolysis bullosa. Actas Dermosifiliogr 2015; 106:376-82. [PMID: 25796272 DOI: 10.1016/j.ad.2015.01.007] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 01/12/2015] [Indexed: 02/07/2023] Open
Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is among the most serious rare skin diseases. It is also the rare skin disease for which most effort has been expended in developing advanced therapeutic interventions. RDEB is caused by collagen VII deficiency resulting from COL7A1 mutations. Therapeutic approaches seek to replenish collagen VII and thus restore dermal-epidermal adhesion. Therapeutic options under development include protein therapy and different cell-based and gene-based therapies. In addition to treating skin defects, some of these therapies may also target internal mucosa. In the coming years, these novel therapeutic approaches should substantially improve the quality of life of patients with RDEB.
Collapse
Affiliation(s)
- F Larcher
- División de Biomedicina Epitelial, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, España; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, España; Instituto de Investigaciones Sanitarias de la Fundación Jimenez Díaz (IIS-FJD), Madrid, España.
| | - M Del Río
- División de Biomedicina Epitelial, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, España; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, España; Instituto de Investigaciones Sanitarias de la Fundación Jimenez Díaz (IIS-FJD), Madrid, España; Departamento de Bioingeniería, Universidad Carlos III de Madrid (UC3M), Madrid, España
| |
Collapse
|
44
|
Gallego A, Rogel R, Luján S, Plaza B, Delgado F, Boronat F. AZF gene microdeletions: case series and literature review. Actas Urol Esp 2014; 38:698-702. [PMID: 24954841 DOI: 10.1016/j.acuro.2014.04.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2014] [Accepted: 04/10/2014] [Indexed: 11/21/2022]
Abstract
OBJECTIVE Aproximately 10% of patients with non-obstructive azoospermia and 5% with non-obstructive severe oligozoospermia carry AZF region microdeletions (AZoospermic Factor) in the Y chromosome. The aim of this study is to analize the clinical and pathological findings in this group of patients and compare them with the previous evidence. MATERIAL AND METHODS Retrospective study of 11 patients with diagnosis of azoospermia or oligozoospermia and the presence of AZFa, AZFb, AZFc microdeletions or any combination of them. RESULTS Microdeletions of AZFc region were found in 45% of cases, AZFa in 33% and a 10% showed a deletion of the three regions (a,b and c). 91% of them demonstrated azoospermia with low testicular volume in 62,5% cases. CONCLUSION Microdeletions of AZF regions are associated with azoospermia and a low expectation of sperm retrieval in testicular biopsy. On the other hand, they seem not related with significative modifications on the hormone profile.
Collapse
|
45
|
Domingo D, Neco P, Fernández-Pons E, Zissimopoulos S, Molina P, Olagüe J, Suárez-Mier MP, Lai FA, Gómez AM, Zorio E. Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia. ACTA ACUST UNITED AC 2014; 68:398-407. [PMID: 25440180 DOI: 10.1016/j.rec.2014.04.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Accepted: 04/28/2014] [Indexed: 11/18/2022]
Abstract
INTRODUCTION AND OBJECTIVES Catecholaminergic polymorphic ventricular tachycardia is a malignant disease, due to mutations in proteins controlling Ca(2+) homeostasis. While the phenotype is characterized by polymorphic ventricular arrhythmias under stress, supraventricular arrhythmias may occur and are not fully characterized. METHODS Twenty-five relatives from a Spanish family with several sudden deaths were evaluated with electrocardiogram, exercise testing, and optional epinephrine challenge. Selective RyR2 sequencing in an affected individual and cascade screening in the rest of the family was offered. The RyR2(R420Q) mutation was generated in HEK-293 cells using site-directed mutagenesis to conduct in vitro functional studies. RESULTS The exercise testing unmasked catecholaminergic polymorphic ventricular tachycardia in 8 relatives (sensitivity = 89%; positive predictive value = 100%; negative predictive value = 93%), all of them carrying the heterozygous RyR2(R420Q) mutation, which was also present in the proband and a young girl without exercise testing, a 91% penetrance at the end of the follow-up. Remarkably, sinus bradycardia, atrial and junctional arrhythmias, and/or giant post-effort U-waves were identified in patients. Upon permeabilization and in intact cells, the RyR2(R420Q) expressing cells showed a smaller peak of Ca(2+) release than RyR2 wild-type cells. However, at physiologic intracellular Ca(2+) concentration, equivalent to the diastolic cytosolic concentration, the RyR2(R420Q) released more Ca(2+) and oscillated faster than RyR2 wild-type cells. CONCLUSIONS The missense RyR2(R420Q) mutation was identified in the N-terminus of the RyR2 gene in this highly symptomatic family. Remarkably, this mutation is associated with sinus bradycardia, atrial and junctional arrhythmias, and giant U-waves. Collectively, functional heterologous expression studies suggest that the RyR2(R420Q) behaves as an aberrant channel, as a loss- or gain-of-function mutation depending on cytosolic intracellular Ca(2+) concentration.
Collapse
Affiliation(s)
- Diana Domingo
- Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Patricia Neco
- Inserm, U769, Université de Paris Sud, IFR141, LabEx Lermit, Châtenay-Malabry, France
| | - Elena Fernández-Pons
- Grupo de Investigación acreditado de Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - Spyros Zissimopoulos
- Wales Heart Research Institute, Cardiff University School of Medicine, Cardiff, United Kingdom
| | - Pilar Molina
- Servicio de Histopatología, Instituto de Medicina Legal, Valencia, Spain
| | - José Olagüe
- Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - M Paz Suárez-Mier
- Servicio de Histopatología, Instituto Nacional de Toxicología y Ciencias Forenses, Madrid, Spain
| | - F Anthony Lai
- Wales Heart Research Institute, Cardiff University School of Medicine, Cardiff, United Kingdom
| | - Ana M Gómez
- Inserm, U769, Université de Paris Sud, IFR141, LabEx Lermit, Châtenay-Malabry, France
| | - Esther Zorio
- Servicio de Cardiología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
| |
Collapse
|
46
|
Soriano-Ferrer M, Piedra Martínez E. A review of the neurobiological basis of dyslexia in the adult population. Neurologia 2014; 32:50-57. [PMID: 25444408 DOI: 10.1016/j.nrl.2014.08.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2014] [Accepted: 08/08/2014] [Indexed: 01/18/2023] Open
Abstract
INTRODUCTION Adult dyslexia affects about 4% of the population. However, studies on the neurobiological basis of dyslexia in adulthood are scarce compared to paediatric studies. AIM This review investigates the neurobiological basis of dyslexia in adulthood. DEVELOPMENT Using PsycINFO, a database of psychology abstracts, we identified 11 studies on genetics, 9 neurostructural studies, 13 neurofunctional studies and 24 neurophysiological studies. Results from the review show that dyslexia is highly heritable and displays polygenic transmission. Likewise, adult neuroimaging studies found structural, functional, and physiological changes in the parieto-occipital and occipito-temporal regions, and in the inferior frontal gyrus, in adults with dyslexia. CONCLUSION According to different studies, aetiology in cases of adult dyslexia is complex. We stress the need for neurobiological studies of dyslexia in languages with transparent spelling systems.
Collapse
Affiliation(s)
- M Soriano-Ferrer
- Departamento de Psicología Evolutiva y de la Educación, Facultad de Psicología, Universidad de Valencia, Valencia, España.
| | - E Piedra Martínez
- Escuela de Educación Especial, Escuela de Psicología Educativa, Facultad de Filosofía, Universidad del Azuay, Cuenca, Ecuador
| |
Collapse
|
47
|
Ferrán A, Alegret JM, Subirana I, Aragonès G, Lluis-Ganella C, Romero-Menor C, Planas F, Joven J, Elosua R. Association between rs2200733 and rs7193343 genetic variants and atrial fibrillation in a Spanish population, and meta-analysis of previous studies. Rev Esp Cardiol (Engl Ed) 2014; 67:822-9. [PMID: 25262128 DOI: 10.1016/j.rec.2013.12.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Accepted: 12/19/2013] [Indexed: 02/03/2023]
Abstract
INTRODUCTION AND OBJECTIVES The objectives of this study were to analyze the association between two genetic variants (rs2200733 and rs7193343) in a Spanish population and the risk of developing atrial fibrillation, and to carry out a systematic review and meta-analysis of these associations. METHODS We performed a case-control study involving 257 case patients with atrial fibrillation and 379 controls. The case patients were individuals who had donated samples to the Spanish National DNA Bank; the controls were participating in a population-based cross-sectional study. Genotyping was carried out using a TaqMan assay. We conducted a systematic literature search in which 2 independent reviewers extracted the necessary information. The study involved a meta-analysis, a heterogeneity analysis, and a meta-regression analysis to identify the variables that explain the heterogeneity across studies. RESULTS In our population, the presence of atrial fibrillation was found to be associated with rs2200733 (odds ratio = 1.87; 95% confidence interval, 1.30-2.70), but not with rs7193343 (odds ratio = 1.18; 95% confidence interval, 0.80-1.73). In the meta-analysis, we observed an association between atrial fibrillation and both variants: odds ratio = 1.71 (95% confidence interval, 1.54-1.90) for rs2200733 and odds ratio = 1.18 (95% confidence interval, 1.11-1.25) for rs7193343. We observed heterogeneity among the studies dealing with the association between rs2200733 and atrial fibrillation, partially related to the study design, and the strength of association was greater in case-control studies (odds ratio = 1.83) than in cohort studies (odds ratio = 1.41). CONCLUSIONS Variants rs2200733 and rs7193343 are associated with a higher risk of atrial fibrillation. Case-control studies tend to overestimate the strength of association between these genetic variants and atrial fibrillation.
Collapse
Affiliation(s)
- Albert Ferrán
- Grupo de Investigación en Epidemiología y Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain
| | - José María Alegret
- Sección de Cardiología, Hospital Universitari de Sant Joan, Grup de Recerca Cardiovascular, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain
| | - Isaac Subirana
- Grupo de Investigación en Epidemiología y Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain; CIBER de Epidemiología y Salud Pública, Barcelona, Spain
| | - Gerard Aragonès
- Sección de Cardiología, Hospital Universitari de Sant Joan, Grup de Recerca Cardiovascular, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain; Centre for Omic Sciences, Servei de Recursos Científics i Tècnics, Universitat Rovira i Virgili, Tarragona, Spain
| | - Carla Lluis-Ganella
- Grupo de Investigación en Epidemiología y Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain
| | - César Romero-Menor
- Servicio de Cardiología, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain
| | - Francesc Planas
- Servicio de Cardiología, Hospital Municipal de Badalona, Badalona, Barcelona, Spain
| | - Jorge Joven
- Unidad de Investigación Biomédica (URB-CRB), IISPV, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, Reus, Tarragona, Spain
| | - Roberto Elosua
- Grupo de Investigación en Epidemiología y Genética Cardiovascular, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain.
| |
Collapse
|
48
|
López Fernández JC, Rodríguez Esparragón F, Buset Ríos N. [Update on the genetics of stroke]. Med Clin (Barc) 2014; 143:176-9. [PMID: 24703417 DOI: 10.1016/j.medcli.2014.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 02/03/2014] [Accepted: 02/06/2014] [Indexed: 10/25/2022]
Abstract
Stroke is a disease with significant morbidity, mortality, and economic and social impacts. It is a complex entity whose pathogenesis involves multiple environmental and genetic factors, with the latter having a role in up to 50% of strokes. The objective of the review is to analyze the available methods for the genetic diagnosis including linkage studies of variation in copy number, gene - candidate approximations, or whole genome (GWAS) and polymorphisms associated with its pathogenesis. We describe several single nucleotide polymorphisms (SNPs) associated with stroke in association studies and GWAS such as SNPs of angiotensin, the aldosterone system, paraoxonases, nitric oxide, coagulation, and fibrinolysis system, among others. We also analyze the role of certain polymorphisms in the phenotype of the carotid plaque, intracranial aneurysms and lobar hemorrhages. Pharmacogenomic aspects in which SNPs affect the response and safety regarding the use of different drugs are also described. Several SNPs that significantly contribute to the risk of stroke are also described. The advent of techniques like GWAS has contributed to the understanding of genetics and pharmacogenomics of stroke.
Collapse
Affiliation(s)
- Juan Carlos López Fernández
- Servicio de Neurología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España.
| | | | - Nisa Buset Ríos
- Unidad de Investigación, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España
| |
Collapse
|
49
|
Lerín M, Prados C, Martínez MT, Maíz L, Girón R, Solé A, Cabanillas JJ, Alvarez-Sala R. Cystic fibrosis in adult age. Rev Clin Esp 2014; 214:289-95. [PMID: 24948579 DOI: 10.1016/j.rce.2014.05.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Revised: 04/01/2014] [Accepted: 05/03/2014] [Indexed: 11/28/2022]
Abstract
AIM To know the prevalence of the patients diagnosed of cystic fibrosis (CF) older than 18 years old of five specific Spanish Units and to analyze their clinical, genetic and microbiological characteristics. PATIENTS AND METHODS Observational, cross-sectional, descriptive study of patients diagnosed with CF at age or older than 18 years. The variables analyzed were: current age, age at diagnosis, sex, nationality, lung function parameters, pathologies presented at diagnosis, microbiological features and genetic findings. RESULTS Eigthy nine patients (14.8% of the total of 600 CF patients followed at the participating units), of which 45 patients were female (50.6%) and 44 were males (49.4%), were included with a mean age at diagnosis of 36.4 years. Eigthy one patients (91%) were Spaniards. The sweat test was diagnostic in 77 (86.5%) of the patients studied. The sweat test was diagnostic in 77 of the 89 patients studied (86.5%). The most frequently detected mutations were F508del/other and G542X/other, and the most frequent clinical findings at diagnosis were the presence of bronchiectasis in 33 patients (37.1%) followed by sterility in 12 patients (13.5%). The most common colonizing organisms were meticillin-sensitive Staphylococcus aureus (S.aureus) (23.6%) and Pseudomonas aeruginosa (P. aeruginosa) (13.5%). Most patients presented a mild obstructive ventilatory defect and had no pancreatic involvement. The sweat test used to be indeterminate. CONCLUSIONS CF is also a disease which diagnosis can be in adulthood. CF patients diagnosed in adulthood have a mild lung function and lower incidence of pancreatic involvement, so their prognosis tends to be favorable.
Collapse
Affiliation(s)
- M Lerín
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario La Paz, Madrid, España
| | - C Prados
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario La Paz, Madrid, España.
| | - M T Martínez
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario 12 de Octubre, Madrid, España
| | - L Maíz
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario Ramón y Cajal, Madrid, España
| | - R Girón
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario La Princesa, Madrid, España
| | - A Solé
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario La Fe, Valencia, España
| | - J J Cabanillas
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario La Paz, Madrid, España
| | - R Alvarez-Sala
- Unidad de Fibrosis quística, Servicio de Neumología, Hospital Universitario La Paz, Madrid, España
| |
Collapse
|
50
|
Özdoğan N, Tutar N, Demir R, Saatçi Ç, Kanbay A, Büyükoğlan H. Is TNF-α gene polymorphism related to pulmonary functions and prognosis as determined by FEV1, BMI, COPD exacerbation and hospitalization in patients with smoking-related COPD in a Turkish population? Rev Port Pneumol 2014; 20:305-10. [PMID: 24818527 DOI: 10.1016/j.rppneu.2014.03.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2013] [Revised: 02/04/2014] [Accepted: 03/16/2014] [Indexed: 11/21/2022] Open
Abstract
INTRODUCTION Some conflicting results have been published about the relationship between TNF-α-308 gene polymorphism and chronic obstructive pulmonary disease (COPD). The aim of this study was to determine whether TNF-α-308 gene polymorphism was associated with smoking-related COPD and whether it was associated with pulmonary function parameters (PFTs), body mass index (BMI), and prognosis. METHODS We studied the frequencies of TNF-α-308 gene polymorphism in 90 male subjects (60 subjects with COPD and 30 healthy smokers) in a Caucasian population. RESULTS There was no significant difference in the frequency of G/G and G/A gene polymorphisms in the COPD group compared with control subjects (p>0.05). We compared COPD patients as G/A gene polymorphism and G/G gene polymorphism; the PFTs and BMI before and after one year were not statistically significant (p>0.05). Also, the exacerbation and hospitalization data of COPD patients were not significant between these groups. CONCLUSION In conclusion, there was no difference between smoking-related COPD and the control group according to TNF α-308 gene polymorphism in a Caucasian population. In addition, it was shown that important determinants of prognosis of COPD such as FEV1, BMI, COPD exacerbation and hospitalization were not associated with TNF-α-308 gene polymorphism.
Collapse
|